Uricase, its pharmaceutical composition and use thereof
By mutation of uridase amino acid sequence and replacement of cysteine residues, and covalently modifying with polyethylene glycol, forming uridase conjugates, the immunogenicity and half-life of existing uridase drugs are solved. , achieving safer and more convenient treatment for hyperuricemia.
Patent Information
- Application Number
- CN202210378688.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-04-09
- Filing Date
- 2022-04-08
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-04-08
AI Technical Summary
Existing uricase drugs have immunogenic reactions, allergic reactions and short half-life when treating hyperuricemia, resulting in insufficient safety and convenience of use, and require intravenous injection, affecting the patient's quality of life.
A uridase variant was developed that contains specific amino acid sequence mutations and cysteine residue replacements, and covalently modified by polymers such as polyethylene glycol (PEG) to form uridase conjugates to reduce immunity Originating and prolonging the half-life to form a safer and more convenient form of the drug.
It improves the safety and convenience of the drug, reduces the risk of immune response, extends the half-life, and achieves a more effective uric acid reduction effect, which is suitable for the treatment of hyperuricemia.
Smart Images

Figure BDA0003587209820000141 
Figure BDA0003587209820000142 
Figure BDA0003587209820000143
Abstract
Description
Technical Field
[0001] The present invention relates to the field of therapeutic drugs, and in particular to uricase, a pharmaceutical composition thereof and uses thereof. Background Art
[0002] Gout and hyperuricemia are common diseases that endanger human health. According to statistics, the incidence of hyperuricemia has reached 10% of the population. Gout is an acute arthritis caused by the precipitation of urate crystals in the joints due to excessively high blood uric acid levels. On the one hand, with the changes in people's diet and living habits, the intake of high-protein and high-purine foods has increased, and the number of gout patients has increased year by year; on the other hand, after radiotherapy and chemotherapy, some malignant tumors, especially leukemia and lymphoma patients, will have a large amount of uric acid deposited in the kidneys in a short period of time, causing renal failure. In recent decades, many scientists have been committed to using uricases from other species for the treatment of human hyperuricemia-related diseases. However, one of the biggest problems with the application of foreign proteins in the human body is the anti-protein reaction and allergic reaction caused by the immunogenicity of the protein. Later, scientists used ethylene glycol (PEG) to covalently modify the protein, which proved to reduce the immunogenicity of the protein, increase the solubility of the protein and prolong the half-life of the protein.
[0003] There are currently two clinically approved uricase drugs, one of which is Krystexxa and the other is Elitek. Krystexxa (pegloticase) is a pegloticase approved for the treatment of chronic gout in adult patients refractory to conventional therapy. It is a chimeric protein of highly peglotized pig and baboon uricase sequences that can be administered within 2 hours by intravenous injection. Krystexxa contains a black box warning for allergic reactions and infusion reactions. Elitek (rasburicase) is a modified recombinant Aspergillus flavus uricase indicated for the initial management of plasma uric acid levels in children and adult patients with leukemia, lymphoma and solid tumor malignancies who receive anticancer treatment that is expected to cause tumor lysis and subsequent increase in plasma uric acid. However, Elitek has a half-life of 16-21 hours in the body and must be administered daily via intravenous infusion. Similarly, Elitek also has a black box warning for allergic reactions and hemolysis.
[0004] In view of the above situation, there is an urgent need in the art to develop safer, more convenient and less immunogenic drugs for treating hyperuricemia. Summary of the invention
[0005] In one aspect, the present invention provides a uricase comprising an amino acid sequence as shown in SEQ ID NO: 9 or a variant thereof that retains enzyme activity, wherein the mutation of the variant relative to SEQ ID NO: 9 comprises: substitution of amino acid residues within 17 at the N-terminus and / or substitution of amino acid residues within 10 at the C-terminus.
[0006] In some embodiments, the mutation of the variant relative to SEQ ID NO: 9 includes: the N-terminal amino acid sequence MTAETSTGTKVVLGQ is replaced by MANIILGK, and / or the C-terminal amino acid sequence SRADHPIWSN is replaced by C.
[0007] In some embodiments, the uricase comprises the sequence shown in SEQ ID NO: 10 or SEQ ID NO: 11, respectively.
[0008] In some embodiments, the variant mutations relative to SEQ ID NO:9 also include the introduction of 1, 2, 3, 4 or 5 surface accessible cysteine residues at 1, 2, 3, 4 or 5 positions selected from 35, 82, 142, 194, 216, 287 and 288, wherein the position numbers are relative to the position numbers of SEQ ID NO:3.
[0009] In some embodiments, the variant mutation relative to SEQ ID NO:9 also includes the introduction of two surface accessible cysteine residues at two positions selected from 35, 82, 142, 194, 216, 287 and 288, wherein the position numbers are relative to the position numbers of SEQ ID NO:3.
[0010] In some embodiments, the variant comprises a mutation relative to SEQ ID NO:9 that includes a cysteine residue at two of the following positions: 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 194, or 82 and 287, wherein the position numbers are relative to the position numbers of SEQ ID NO:3.
[0011] In some embodiments, the variant further comprises a substitution mutation at position 205 and / or position 208 relative to SEQ ID NO: 9, wherein the position number is relative to the position number of SEQ ID NO: 3. Preferably, the substitution mutation is that S at position 205 is substituted with D or E, and G at position 208 is substituted with R, K or S. In some embodiments, the substitution mutation is S205D or G208R or a combination thereof.
[0012] In some embodiments, the uricase described in the present invention comprises the amino acid sequence shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20.
[0013] In yet another aspect, the present invention provides a uricase conjugate (i.e., a modified uricase) comprising the uricase described herein and a polymer covalently linked or fused to the uricase. In some embodiments, the polymer is selected from polyethylene glycol (PEG), a phosphorylcholine polymer, a polymer of a repeating peptide or "X-TEN" sequence, and a carbohydrate-based polymer. In some embodiments, the polymer is fused to the N-terminus and / or C-terminus of the uricase, or is covalently linked via a cysteine residue present on the uricase.
[0014] In some embodiments, the polymer is PEG, which is covalently attached via a cysteine residue present on the uricase. Preferably, the uricase has 1, 2, 3, 4 or 5 surface accessible cysteine residues at 1, 2, 3, 4 or 5 positions selected from 35, 82, 142, 194, 216, 287 and 288, wherein the position numbering is relative to the position numbering of SEQ ID NO: 3, and the PEG is covalently attached via the cysteine residues at these positions. More preferably, the uricase comprises cysteine residues at two of the following positions: 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 194, or 82 and 287, respectively, wherein the position numbering is relative to the position numbering of SEQ ID NO: 3, and the PEG is covalently attached via the cysteine residues at these positions.
[0015] In some embodiments, the uricase comprises a cysteine residue at position 288, and the PEG is covalently attached via the cysteine residue at this position, wherein the position numbering is relative to the position numbering of SEQ ID NO: 10.
[0016] In some embodiments, the amino acid sequence of the uricase is as shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, and the PEG is covalently attached to the amino acid sequence through positions 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 288, 35 and 194, 82 and 287, 35 and 194, and 142 and 216 of the amino acid sequence, respectively, wherein the position numbers are relative to the position numbers of SEQ ID NO:3.
[0017] In some embodiments, the amino acid sequence of the uricase is as shown in SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 16, and the PEG is also covalently linked to the amino acid sequence through position 288 of the amino acid sequence, wherein the position number is relative to the position number of SEQ ID NO: 10.
[0018] In some embodiments, the amino acid sequence of the uricase is as shown in SEQ ID NO: 17, and the PEG is covalently linked via cysteine residues 35 and 194, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3.
[0019] In yet another aspect, the present invention provides a pharmaceutical composition comprising: (1) a buffer; and (2) a uricase or a uricase conjugate as described in any embodiment herein.
[0020] In some embodiments, the uricase conjugate is the PEG-modified uricase described in the present invention.
[0021] In some embodiments, the pH of the pharmaceutical composition is about 6.0-8.5, preferably about 7.0-8.5, and preferably about 7.5-8.1.
[0022] In some embodiments, the uricase of the above pharmaceutical composition comprises the amino acid sequence shown in SEQ ID NO: 12, SEQ ID NO: 13 or SEQ ID NO: 17, respectively.
[0023] In some embodiments, the concentration of uricase or uricase conjugate in the pharmaceutical composition is about 1-300 mg / mL, preferably about 1-250 mg / mL, preferably about 1-200 mg / mL, preferably about 5-80 mg / mL, more preferably 5-40 mg / mL; more preferably 5-20 mg / mL; more preferably, the above uricase concentration is about 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, 10 mg / mL, 12 mg / mL, 14 mg / mL, 16 mg / mL, 18 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL or 140 mg / mL, preferably about 8 mg / mL, 10 mg / mL or 20 mg / mL.
[0024] In some embodiments, the buffer is selected from phosphate buffer, Tris hydrochloric acid buffer, citrate buffer and histidine buffer; preferably, the buffer is phosphate buffer or Tris hydrochloric acid buffer; more preferably, the buffer is disodium hydrogen phosphate-sodium dihydrogen phosphate buffer.
[0025] In some embodiments, the above-mentioned buffer is a phosphate buffer, and preferably, the phosphate buffer is a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer. In some embodiments, the phosphate buffer is made of 1-30mM disodium hydrogen phosphate and 1-30mM sodium dihydrogen phosphate. In some embodiments, the phosphate buffer is made of 17mM disodium hydrogen phosphate and 3mM sodium dihydrogen phosphate monohydrate. In some embodiments, the phosphate buffer is made of 18.5mM disodium hydrogen phosphate and 1.5mM sodium dihydrogen phosphate monohydrate.
[0026] In some embodiments, the above-mentioned buffer is a Tris hydrochloric acid (Tris-HCl) buffer. In some embodiments, the Tris hydrochloric acid buffer is made up of 1-30mM HCl and 1-30mM Tris (tris hydroxymethylaminomethane). In some embodiments, the Tris hydrochloric acid buffer is made up of 11.8mM Tris-HCl and 8.2mM Tris. In some embodiments, the Tris hydrochloric acid buffer is made up of 16.5mM Tris-HCl and 3.5mM Tris. In some embodiments, the Tris hydrochloric acid buffer is made up of 20mM Tris, adding concentrated hydrochloric acid to adjust pH to 7.5 or 8.0.
[0027] In some embodiments, the above buffer is a histidine buffer, preferably, the histidine buffer is selected from histidine-hydrochloride buffer or histidine-acetate buffer.
[0028] In some embodiments, the buffer is a citric acid buffer, and preferably, the citric acid buffer is a citric acid-sodium citrate buffer.
[0029] In some embodiments, the concentration of the buffer is about 1-200mM, preferably about 5-200mM, preferably about 10-50mM, preferably about 10-30mM; preferably about 20-30mM. Non-limiting examples of the concentration of the buffer are about 5mM, 10mM, 15mM, 20mM, 25mM, 30mM, 40mM, 45mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 105mM, 110mM, 115mM, 120mM, 130mM, 140mM, 150mM, 160mM, 170mM or 180mM or a range formed by any two values within these ranges as endpoints, preferably 10mM, 15mM, 20mM or 30mM.
[0030] In some embodiments, the pH of the buffer is about 6.0-8.5, preferably about 6.5-8.5, preferably about 7.0-8.5, preferably about 7.5-8.5, preferably about 7.5-8.1, and non-limiting examples of the pH of the buffer are about 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, preferably about 7.5, 7.6, 7.7, 7.8, 7.9, 8.0 or 8.1, more preferably 7.8.
[0031] In some embodiments, the above-mentioned pharmaceutical composition further comprises a stabilizer, and the stabilizer is selected from one or more of arginine hydrochloride, sodium chloride, mannitol, sucrose and trehalose; preferably, the stabilizer is selected from mannitol, trehalose, a combination of mannitol and sodium chloride, or a combination of trehalose and sodium chloride.
[0032] In some embodiments, the concentration of the stabilizer is about 10 mM to 400 mM, preferably 20 mM to 300 mM, and more preferably 50 mM to 200 mM.
[0033] In some embodiments, the stabilizer is sodium chloride at a concentration of about 30-200 mM; or the stabilizer is mannitol at a concentration of about 100-300 mM; or the stabilizer is sucrose at a concentration of about 100-300 mM; or the stabilizer is trehalose at a concentration of about 100-300 mM; or the stabilizer is arginine hydrochloride at a concentration of about 30-200 mM.
[0034] In some embodiments, the stabilizer is a combination of about 30-200 mM sodium chloride and about 30-200 mM mannitol; or the stabilizer is a combination of about 30-200 mM sodium chloride and about 30-200 mM trehalose; or the stabilizer is a combination of about 30-200 mM sodium chloride and about 30-200 mM sucrose.
[0035] In some embodiments, the stabilizer is sodium chloride. In some embodiments, the stabilizer is sodium chloride with a concentration of about 30-200 mM, preferably about 50-190 mM, preferably about 100-180 mM, preferably about 120-170 mM, preferably about 130-150 mM, and non-limiting examples of the sodium chloride concentration are about 100 mM, 110 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 170 mM, 180 mM, 190 mM, 200 mM, preferably 135 mM or 140 mM.
[0036] In some embodiments, the stabilizer is mannitol. In some embodiments, the stabilizer is mannitol at a concentration of about 100-300 mM, preferably about 150-300 mM, preferably about 200-300 mM, and a non-limiting example of the concentration of mannitol is about 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, preferably 240 mM.
[0037] In some embodiments, the stabilizer is sucrose. In some embodiments, the stabilizer is sucrose at a concentration of about 100-300 mM, preferably about 150-300 mM, preferably about 200-300 mM, and a non-limiting example of the sucrose concentration is about 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, preferably 220 mM.
[0038] In some embodiments, the stabilizer is trehalose. In some embodiments, the stabilizer is trehalose at a concentration of about 100-300 mM, preferably about 150-300 mM, preferably about 200-300 mM, and a non-limiting example of the concentration of trehalose is about 180 mM, 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, preferably 220 mM.
[0039] In some embodiments, the stabilizer is arginine hydrochloride. In some embodiments, the stabilizer is arginine hydrochloride at a concentration of about 30-200 mM, preferably about 50-190 mM, preferably about 100-180 mM, preferably about 120-170 mM, preferably about 130-150 mM, and the non-limiting example of the concentration of arginine hydrochloride is about 100 mM, 110 mM, 120 mM, 125 mM, 130 mM, 135 mM, 140 mM, 145 mM, 150 mM, 155 mM, 160 mM, 170 mM, 180 mM, 190 mM, 200 mM, preferably 135 mM or 140 mM.
[0040] In some embodiments, the stabilizer is a combination of sodium chloride and mannitol. In some embodiments, the stabilizer is a combination of about 30-200mM sodium chloride and about 30-200mM mannitol, preferably a combination of about 30-150mM sodium chloride and about 40-200mM mannitol, preferably a combination of about 30-100mM sodium chloride and about 100-180mM mannitol, and a non-limiting example of the stabilizer is a combination of about 50mM sodium chloride and about 140mM mannitol.
[0041] In some embodiments, the stabilizer is a combination of sodium chloride and sucrose. In some embodiments, the stabilizer is a combination of about 30-200 mM sodium chloride and about 30-200 mM sucrose, preferably a combination of about 30-150 mM sodium chloride and about 40-200 mM sucrose, preferably a combination of about 30-100 mM sodium chloride and about 100-180 mM sucrose, and a non-limiting example of the stabilizer is a combination of about 50 mM sodium chloride and about 140 mM sucrose.
[0042] In some embodiments, the stabilizer is a combination of sodium chloride and trehalose. In some embodiments, the stabilizer is a combination of about 30-200 mM sodium chloride and about 30-200 mM trehalose, preferably a combination of about 30-150 mM sodium chloride and about 40-200 mM trehalose, preferably a combination of about 30-100 mM sodium chloride and about 100-180 mM trehalose, and a non-limiting example of the stabilizer is a combination of about 50 mM sodium chloride and about 140 mM trehalose.
[0043] In some embodiments, the pharmaceutical composition further comprises a surfactant selected from polysorbate 80, polysorbate 20 or poloxamer 188.
[0044] In some embodiments, the surfactant is selected from polysorbate 80.
[0045] In some embodiments, the surfactant is selected from polysorbate 20.
[0046] In some embodiments, the concentration of the above-mentioned surfactant is about 0.001%-0.1%, preferably about 0.01%-0.1%, preferably about 0.02%-0.08% calculated on a w / v basis; as a non-limiting example, the concentration of the above-mentioned surfactant is about 0.02%, 0.04% or 0.08%, preferably 0.02%.
[0047] In some embodiments, the pharmaceutical composition herein comprises the components shown in any one of the following (1)-(5), or is respectively composed of the components shown in any one of the following (1)-(5):
[0048] (1) (a) about 5 mg / mL to 40 mg / mL of uricase or uricase conjugate; (b) about 10-30 mM phosphate buffer, pH about 7.5-8.1; (c) about 100-300 mM mannitol; and (d) about 0.01% to 0.1% polysorbate 80; or
[0049] (2) (a) about 5 mg / mL to 40 mg / mL of uricase or uricase conjugate; (b) about 10-30 mM Tris hydrochloric acid buffer, pH about 7.5-8.1; (c) about 100-300 mM trehalose; and (d) about 0.01% to 0.1% polysorbate 80; or
[0050] (3) (a) about 5 mg / mL to 40 mg / mL of uricase or uricase conjugate; (b) about 10-30 mM phosphate buffer, pH about 7.5-8.1; (c) about 100-300 mM trehalose; and (d) about 0.01% to 0.1% polysorbate 80; or
[0051] (4) (a) about 5 mg / mL to 40 mg / mL of uricase or uricase conjugate; (b) about 10-30 mM phosphate buffer, pH about 7.5-8.1; (c) a combination of about 30-200 mM sodium chloride and about 30-200 mM mannitol; and (d) about 0.01% to 0.1% polysorbate 80; or
[0052] (5) (a) about 5 mg / mL-40 mg / mL of uricase or uricase conjugate; (b) about 10-30 mM phosphate buffer, pH about 7.5-8.1; (c) a combination of about 30-200 mM sodium chloride and about 30-200 mM trehalose; and (d) about 0.01%-0.1% polysorbate 80.
[0053] Preferably, the uricase is as described in any embodiment herein.
[0054] In some embodiments, the pharmaceutical composition comprises the components shown in any one of the following (1)-(5), or is respectively composed of the components shown in any one of the following (1)-(5):
[0055] (1) (a) about 8 mg / mL of uricase or uricase conjugate; (b) about 20 mM phosphate buffer, pH about 7.5-7.8; (c) about 240 mM mannitol; and (d) about 0.02% polysorbate 80; or
[0056] (2) (a) about 8 mg / mL of uricase or uricase conjugate; (b) about 20 mM Tris-HCl buffer, pH about 7.5-8.0; (c) about 220 mM trehalose; and (d) about 0.02% polysorbate 80; or
[0057] (3) (a) about 8 mg / mL of uricase or uricase conjugate; (b) about 20 mM phosphate buffer, pH about 7.5-7.8; (c) about 220 mM trehalose; and (d) about 0.02% polysorbate 80; or
[0058] (4) (a) about 8 mg / mL of uricase or uricase conjugate; (b) about 20 mM phosphate buffer, pH about 7.5-7.8; (c) a combination of about 50 mM sodium chloride and about 140 mM mannitol; and (d) about 0.02% polysorbate 80; or
[0059] (5) (a) about 8 mg / mL of uricase or uricase conjugate; (b) about 20 mM phosphate buffer, pH about 7.5-7.8; (c) a combination of about 50 mM sodium chloride and about 140 mM trehalose; and (d) about 0.02% polysorbate 80.
[0060] Preferably, the uricase or uricase conjugate is as described in any embodiment herein.
[0061] In some embodiments, the pharmaceutical composition is a liquid preparation or a lyophilized preparation.
[0062] In some embodiments, the pharmaceutical composition is a liquid preparation.
[0063] In some embodiments, the liquid formulation or lyophilized formulation is stable at 2-8° C. for at least 2 months, 3 months, at least 6 months, at least 12 months, at least 18 months or at least 24 months.
[0064] In some embodiments, the aqueous solution or lyophilized formulation is stable at 23-27° C. for at least 2 weeks, at least 4 weeks, or at least 8 weeks.
[0065] In some embodiments, the aqueous solution or lyophilized formulation is stable at 40° C. for at least 7 days, at least 14 days, or at least 28 days.
[0066] The present invention also provides an injection, which contains the pharmaceutical composition according to any embodiment of the present invention and 0.9wt% sodium chloride solution or 5wt% glucose aqueous solution; preferably, in the injection containing 0.9wt% sodium chloride solution, the concentration of uricase is 0.2-4mg / mL, and in the injection containing 5wt% glucose aqueous solution, the concentration of uricase is 1-4mg / mL; preferably, the pH of the injection is 7.5-8.1.
[0067] The present invention also provides the use of the above-mentioned uricase, uricase conjugate or pharmaceutical composition in the preparation of a drug for reducing the uric acid level in mammalian body fluids and tissues or treating hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS
[0068] Figure 1 : Comparison of the specific enzyme activities of various uricases.
[0069] Figure 2 :Thermostability experiments of various uricases.
[0070] Figure 3 :Study on the thermal stability of various uricases. 3a: PR-HPLC analysis of protein molecules at 4℃; 3b: SEC-HPLC analysis of protein molecules at 4℃.
[0071] Figure 4:Evaluation of the kinetics of PEGylated uricase enzymatic activity.
[0072] Figure 5 : Evaluation of thermal stability of PEGylated uricase.
[0073] Figure 6 : In vivo efficacy evaluation of PEGylated uricase. DETAILED DESCRIPTION
[0074] Definition and Description
[0075] In order to more easily understand the present invention, some technical and scientific terms are specifically defined below. Unless otherwise clearly defined in this article, all other technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs. It should be understood that the present invention is not limited to specific methods, reagents, compounds, compositions or biosystems, and certainly the above can be changed. It should also be understood that the application's terms are only for the purpose of describing specific embodiments and are not intended to be limiting.
[0076] Unless the content clearly dictates otherwise, the singular forms "a", "an" and "the" used in this specification and the appended claims include plural references. Thus, for example, reference to "a polypeptide" includes combinations of two or more polypeptides, etc.
[0077] The term "pharmaceutical composition" or "preparation" refers to a mixture containing one or more antibodies described herein and other components, such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.
[0078] The term "liquid formulation" refers to a formulation in a liquid state, and is not intended to refer to a resuspended lyophilized formulation. The liquid formulation of the present invention is stable upon storage, and its stability is not dependent on lyophilization (or other state-changing methods, such as spray drying).
[0079] The term "aqueous liquid formulation" refers to a liquid formulation using water as a solvent. In some embodiments, the aqueous liquid formulation is a formulation that does not require lyophilization, spray drying and / or freezing to maintain stability (eg, chemical and / or physical stability and / or biological activity).
[0080] The term "excipient" refers to an agent that can be added to a formulation to provide desired properties (e.g., consistency, increased stability) and / or to adjust osmotic pressure. Examples of commonly used excipients include, but are not limited to, sugars, polyols, amino acids, surfactants, and polymers.
[0081] As used herein, "about" when referring to a measurable value (eg, an amount, a duration, etc.) is intended to encompass variations of ±20% or ±10% relative to the particular value, including ±5%, ±1%, and ±0.1%, as such variations are suitable for performing the disclosed methods.
[0082] The term "buffer pH of about 6.0-8.5" refers to an agent that, through the action of its acid / base conjugate components, renders the solution containing the agent resistant to pH changes. The buffer used in the formulations of the present invention may have a pH in the range of about 6.0 to about 8.5, or a pH in the range of about 7.0 to about 8.5, or a pH in the range of about 7.5 to about 8.1.
[0083] Herein, examples of "buffers" that control the pH within this range include acetate (e.g., sodium acetate), Tris hydrochloride, succinate (e.g., sodium succinate), gluconic acid, histidine, histidine hydrochloride, methionine, citrate, phosphate, citrate / phosphate, imidazole, acetic acid, acetate, citrate, combinations thereof, and other organic acid buffers.
[0084] "Phosphate buffer" is a buffer comprising phosphate ions. Examples of phosphate buffers include disodium hydrogen phosphate-sodium dihydrogen phosphate, dipotassium hydrogen phosphate-potassium dihydrogen phosphate, and the like. A preferred phosphate buffer is disodium hydrogen phosphate-sodium dihydrogen phosphate buffer.
[0085] "Tris-HCl buffer" is a tris-hydroxymethylaminomethane hydrochloride buffer, also known as Tris-HCl buffer. Tris-HCl buffer includes Tris and HCl.
[0086] "Histidine buffer" is a buffer containing histidine ions. Examples of histidine buffer include histidine and histidine salts, such as histidine hydrochloride, histidine acetate, histidine phosphate and histidine sulfate, such as a histidine buffer containing histidine and histidine hydrochloride.
[0087] "Citrate buffer" is a buffer comprising citrate ions. Examples of citrate buffers include citric acid-sodium citrate, citric acid-potassium citrate, citric acid-calcium citrate, citric acid-magnesium citrate, and the like. A preferred citrate buffer is citric acid-sodium citrate buffer.
[0088] The term "stabilizer" refers to a pharmaceutically acceptable excipient that protects the active pharmaceutical ingredient and / or formulation from chemical and / or physical degradation during manufacture, storage and use. Stabilizers include, but are not limited to, sugars, amino acids, salts, polyols and their metabolites as defined below, such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, trehalose, arginine or its salts (such as arginine hydrochloride), glycine, alanine (α-alanine, β-alanine), betaine, leucine, lysine, glutamic acid, aspartic acid, proline, 4-hydroxyproline, sarcosine, γ-aminobutyric acid (GABA), opines, alanine, octopine, strombine) and trimethylamine N-oxide (TMAO), human serum albumin (hsa), bovine serum albumin (bsa), α-casein, globulin, α-lactalbumin, LDH, lysozyme, myoglobin, ovalbumin and RNAaseA. Some stabilizers, such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, etc., can also play a role in controlling osmotic pressure. The stabilizer specifically used in the present invention is selected from one or more of polyols, amino acids, salts, and sugars. Preferred salts are sodium chloride, preferred sugars are sucrose and trehalose, and preferred polyols are mannitol. Preferred amino acids are arginine or its salt (such as arginine hydrochloride), glycine, and proline. Preferred stabilizers are sodium chloride, mannitol, sucrose, trehalose, arginine hydrochloride, sodium chloride-mannitol, sodium chloride-sucrose, and sodium chloride-trehalose.
[0089] The term "surfactant" generally includes agents that protect proteins such as antibodies from air / solution interface-induced stress, solution / surface-induced stress to reduce the aggregation of antibodies or minimize the formation of particulate matter in the formulation. Exemplary surfactants include, but are not limited to, nonionic surfactants such as polyoxyethylene sorbitan fatty acid esters (such as polysorbate 20 and polysorbate 80), polyethylene-polypropylene copolymers, polyethylene-polypropylene glycol, polyoxyethylene-stearate, polyoxyethylene alkyl ethers, such as polyoxyethylene monolauryl ether, alkylphenyl polyoxyethylene ether (Triton-X), polyoxyethylene-polyoxypropylene copolymers (poloxamers, Pluronic), sodium lauryl sulfate (SDS).
[0090] The term "isotonic" means that the formulation has substantially the same osmotic pressure as human blood. Isotonic formulations generally have an osmotic pressure of about 250 to 350 mOsm. Isotonicity can be measured using a vapor pressure or freezing point depression osmometer.
[0091] The term "stable" formulation is one in which the antibody substantially maintains its physical stability and / or chemical stability and / or biological activity during the manufacturing process and / or upon storage. A pharmaceutical formulation may be stable even if the antibody contained therein does not retain 100% of its chemical structure or biological function after a period of storage. In some cases, an antibody formulation that maintains about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% of its structure or function after a period of storage may also be considered "stable." Various analytical techniques for measuring protein stability are available in the art and are reviewed in Peptide and Protein Drug Delivery, 247-301, Vincent Lee, ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991), and Jones, A. (1993) Adv. Drug Delivery Rev. 10: 29-90 (both incorporated by reference).
[0092] The stability of the formulation can be measured by determining the percentage of natural antibodies remaining therein (and other methods) after the formulation has been stored at a certain temperature for a certain period of time. Among other methods, the percentage of natural antibodies can be measured by size exclusion chromatography (e.g., size exclusion high performance liquid chromatography [SEC-HPLC]), and "natural" means not aggregated and not degraded. In some embodiments, the stability of the protein is determined by the percentage of monomeric protein in a solution with a low percentage of degradation (e.g., fragmentation) and / or aggregated protein. In some embodiments, the formulation can be stably stored at room temperature, about 25-30°C or 40°C for at least 2 weeks, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months, or longer, with no more than about 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% aggregated form of antibodies.
[0093] Stability can be measured by determining the percentage of antibody that migrates in the more acidic fraction of the main fraction of the antibody (the "major charged form") during ion exchange (among other methods), where stability is inversely proportional to the percentage of the antibody in the acidic form. The percentage of "acidified" antibody can be measured by ion exchange chromatography (e.g., cation exchange high performance liquid chromatography [CEX-HPLC]), among other methods. In some embodiments, an acceptable level of stability means that after a formulation is stored at a certain temperature for a certain period of time, no more than about 49%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5% or 0.1% of the antibody is detectable in the acidic form. The storage period before measuring stability can be at least 2 weeks, at least 28 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months, at least 18 months, at least 24 months, or longer. When evaluating stability, the temperature at which the pharmaceutical preparation is allowed to be stored can be any temperature in the range of about -80°C to about 45°C, such as storage at about -80°C, about -30°C, about -20°C, about 0°C, about 2-8°C, about 5°C, about 25°C, or about 40°C.
[0094] An antibody "retains its physical stability" in the pharmaceutical composition if it shows substantially no signs of, for example, aggregation, precipitation, and / or denaturation when visually inspected for color and / or clarity or when measured by UV light scattering or by size exclusion chromatography. Aggregation is the process by which individual molecules or complexes associate covalently or non-covalently to form aggregates. Aggregation may proceed to the extent that a visible precipitate is formed.
[0095] The stability of the formulation, e.g., physical stability, can be assessed by methods known in the art, including measuring the apparent extinction (absorbance or optical density) of a sample. Such extinction measurements are related to the turbidity of the formulation. The turbidity of a formulation is, in part, an inherent property of the protein dissolved in solution, and is typically measured by turbidimetry and measured in nephelometric turbidity units (NTU).
[0096] The turbidity level that varies with, for example, the concentration of one or more components in the solution (e.g., protein and / or salt concentration) is also referred to as the "emulsification" or "emulsified appearance" of the formulation. The turbidity level can be calculated with reference to a standard curve generated using a suspension of known turbidity. The reference standard for determining the turbidity level of a pharmaceutical composition can be based on the European Pharmacopoeia standard (European Pharmacopoeia, 4th edition, "Directorate for the Quality of Medicine of the Council of Europe" (EDQM), Strasbourg, France). According to the European Pharmacopoeia standard, a clear solution is defined as a solution having a turbidity less than or equal to the turbidity of a reference suspension having about 3 according to the European Pharmacopoeia standard. Turbidimetric turbidity measurements can detect Rayleigh scattering in the absence of association or non-ideal effects, which generally varies linearly with concentration. Other methods for evaluating physical stability are well known in the art.
[0097] An antibody "retains its chemical stability" in a pharmaceutical composition if its chemical stability at a given time point is such that the antibody is considered to still retain its biological activity as defined below. Chemical stability can be assessed, for example, by detecting or quantifying chemically altered forms of the antibody. Chemical alterations can include size changes (e.g., shortening), which can be assessed using, for example, size exclusion chromatography, SDS-PAGE, and / or matrix-assisted laser desorption ionization / time of flight mass spectrometry (MALDI / TOF MS). Other types of chemical alterations include charge changes (e.g., occurring as a result of deamidation or oxidation), which can be assessed by, for example, ion exchange chromatography.
[0098] An antibody in a pharmaceutical composition "retains its biological activity" if the antibody in the pharmaceutical composition is biologically active for its intended purpose. For example, a formulation of the invention is considered stable if the affinity of uricase contained in the formulation to bind to TIGIT after storage at a temperature such as 5°C, 25°C, 45°C for a certain period of time (e.g., 1 to 12 months) is at least 90%, 95% or more of the binding affinity of the antibody before storage. Binding affinity can also be determined by, for example, ELISA or plasma resonance technology.
[0099] In the context of the present invention, in a pharmacological sense, a "therapeutically effective amount" or "effective amount" of an antibody refers to an amount that is effective in preventing or treating or alleviating the symptoms of a disorder that the antibody can effectively treat. In the present invention, a "therapeutically effective amount" or "therapeutically effective dose" of a drug is any amount of the drug that protects a subject from the onset of the disease or promotes disease regression when used alone or in combination with another therapeutic agent, as evidenced by a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or the prevention of damage or disability caused by disease pain. The ability of a drug to promote disease regression can be evaluated using a variety of methods known to those skilled in the art, such as in human subjects during clinical trials, in animal model systems that predict human efficacy, or by measuring the activity of the agent in an in vitro assay. A therapeutically effective amount of a drug includes a "prophylactically effective amount," i.e., any amount of the drug that inhibits the development or recurrence of a disease when given alone or in combination with other therapeutic drugs to a subject at risk of the disease or a subject with a recurring disease.
[0100] The term "subject" or "patient" is intended to include mammalian organisms. Examples of subjects / patients include humans and non-human mammals, such as non-human primates, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In a specific embodiment of the invention, the subject is a human.
[0101] The terms "administering", "administering" and "treating" refer to introducing a composition comprising a therapeutic agent into a subject using any of a variety of methods or delivery systems known to those skilled in the art. Routes of administration of anti-PD-1 antibodies include intravenous, intramuscular, subcutaneous, peritoneal, spinal or other parenteral routes of administration, such as injection or infusion. "Parenteral administration" refers to administration other than enteral or topical administration, usually by injection, including but not limited to intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraframe, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, intradural and intrasternal injection and infusion and in vivo electroporation.
[0102] "Effective amount" includes an amount sufficient to improve or prevent the symptoms or signs of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount of a particular patient or veterinary subject may vary according to factors such as the condition to be treated, the patient's overall health, the method and route of administration, and the severity of the dosage and side effects. An effective amount may be the maximum dose or dosing regimen to avoid significant side effects or toxic effects. The result may result in a diagnostic measurement or parameter improvement of at least 5%, usually at least 10%, more often at least 20%, most often at least 30%, preferably at least 40%, more preferably at least 50%, most preferably at least 60%, ideally at least 70%, more ideally at least 80%, most ideally at least 90%, wherein 100% is defined as the diagnostic parameter displayed by a normal subject (see, e.g., Maynard et al. (1996) A Handbook of SOPs for Good Clinical Practice, Interpharm Press, Boca Raton, FL; Dent (2001) Good Laboratory and Good Clinical Practice, Urch Publ., London, UK).
[0103] Uricase
[0104] Urate oxidase (uricase)
[0105] Urate oxidase (uricase) is a class of enzymes that catalyzes the oxidation of uric acid, the oxidation product being the more soluble allantoin. Allantoin is a purine metabolite that is more easily excreted. It is a homotetrameric enzyme composed of four identical 34KDa subunits that serves as the initiator of a series of reactions that convert uric acid into a more soluble and more excretable product (allantoin), i.e., uricase catalyzes the reaction of uric acid (UA) with O2 and H2O to form 5-hydroxy-isouric acid ester (HIU) and the release of H2O2. HIU is an unstable product that undergoes non-enzymatic hydrolysis to generate 2-oxo-4-hydroxy-5-ureidoimidazole (OHCU) and then spontaneously decarboxylates to form racemic allantoin. Two additional enzymes (HIU hydrolase and OHCU decarboxylase) are expressed in species containing functional uricases, which can catalyze these reactions more quickly to produce (s)-allantoin. Functional uricase is found in many organisms, such as archaea, bacteria, and eukaryotes. However, uricase is not expressed in humans and some primates. This is due to nonsense mutations at codon 33, codon 187, and mutations at the splice acceptor site in intron 2. In summary, the lack of uricase expression in humans leads to high systemic UA levels and, in some cases, hyperuricemia, such as gout and tumor lysis syndrome. According to conservative estimates, there are currently 120 million hyperuricemia patients in China, and hyperuricemia has become the fourth highest after hypertension, hyperglycemia, and hyperlipidemia. Gout is defined as an inflammatory arthritis in which serum UA levels exceed the solubility of UA in body fluids. Serum UA levels above 6.8 mg / dL can lead to the formation of UA crystals in tissues, causing acute inflammatory reactions. Gout causes chronic pain, functional impairment in work and family life, and impaired health-related quality of life. Tumor lysis syndrome (TLS) refers to a group of clinical syndromes characterized by the rapid dissolution of tumor cells and the release of intracellular metabolites, which causes hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and acute renal failure.
[0106] The uricase of the present invention comprises an amino acid sequence as shown in SEQ ID NO: 9 or a variant thereof that retains enzyme activity, wherein the variant comprises a mutation relative to SEQ ID NO: 9: substitution of amino acid residues within 17 at the N-terminus and / or substitution of amino acid residues within 10 at the C-terminus. The variant of the uricase of the present invention may also comprise a mutation relative to SEQ ID NO: 9 that introduces 1, 2, 3, 4 or 5 surface accessible cysteine residues at 1, 2, 3, 4 or 5 positions selected from 35, 82, 142, 194, 216, 287 and 288, wherein the position numbering is relative to the position numbering of SEQ ID NO: 3. The variant of the uricase of the present invention may also comprise a substitution mutation relative to SEQ ID NO: 9 at position 205 and / or position 208, wherein the position numbering is relative to the position numbering of SEQ ID NO: 3.
[0107] In a preferred embodiment, the mutations of the variant relative to SEQ ID NO: 9 include: the N-terminal amino acid sequence MTAETSTGTKVVLGQ is replaced by MANIILGK, and / or the C-terminal amino acid sequence SRADHPIWSN is replaced by C.
[0108] In a preferred embodiment, the mutation of the uricase variant relative to SEQ ID NO: 9 may further comprise the introduction of two surface accessible cysteine residues at two positions selected from 35, 82, 142, 194, 216, 287 and 288, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3. In a further preferred embodiment, the variant comprises cysteine residues at two of the following positions: 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 194, or 82 and 287, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3.
[0109] In a preferred embodiment, the uricase variant further comprises a mutation relative to SEQ ID NO: 9 in which S at position 205 is substituted with D or E, and G at position 208 is substituted with R, K or S. In some embodiments, the substitution mutation is S205D or G208R or a combination thereof.
[0110] In a preferred embodiment, the amino acid sequence of the uricase variant comprises a sequence as shown in any one of SEQ ID NOs: 10-20, wherein the amino acid sequence of SEQ ID NOs: 12-20 is as follows:
[0111] AG-2C12 / AG-2C12-PEG (SEQ ID NO: 12, Cys mutation based on SEQ ID NO: 9)
[0112]
[0113] AG-2C13 / AG-2C13-PEG (SEQ ID NO: 13, Cys mutation based on SEQ ID NO: 10)
[0114]
[0115] AG-2C16 (SEQ ID NO: 14, Cys mutation based on SEQ ID NO: 9)
[0116]
[0117] AG-2C17 (SEQ ID NO: 15, Cys mutation based on SEQ ID NO: 10)
[0118]
[0119] AG-2C13-1 (SEQ ID NO: 16, Cys mutation based on SEQ ID NO: 10)
[0120]
[0121]
[0122] AG-2C01-2 / AG-2C01-2-PEG (SEQ ID NO: 17, Cys mutation based on SEQ ID NO: 11)
[0123]
[0124] AG-2C05-1 (SEQ ID NO: 18, Cys mutation based on SEQ ID NO: 9)
[0125]
[0126] AG-2C01-1 (SEQ ID NO: 19, Cys mutation based on SEQ ID NO: 11)
[0127]
[0128] AG-2C12-1 (SEQ ID NO: 20, Cys mutation based on SEQ ID NO: 9)
[0129]
[0130] Uricase conjugates (modified uricase)
[0131] The uricase conjugate of the present invention comprises the uricase described herein and a polymer covalently linked or fused to the uricase. In some embodiments, the polymer is selected from polyethylene glycol (PEG), a phosphorylcholine polymer, a polymer of a repeating peptide or "X-TEN" sequence, and a carbohydrate-based polymer. In some embodiments, the polymer is fused to the N-terminus and / or C-terminus of the uricase, or is covalently linked via a cysteine residue present on the uricase.
[0132] Herein, polyethylene glycol (PEG) is a polyol having the structure H-(O-CH2-CH2) n The most commonly used PEG reagent for covalent attachment of proteins is a polyether compound with the structure CH3-O-(CH2-CH2-O) n -Monomethoxy poly (ethylene glycol) derivatives of X, wherein X contains a linear linker and a reactive functional group (linear PEG), and n is an integer from 110 to 18200. In some cases, X may contain a branching element, such that the PEG reagent contains one reactive functional group and more than one PEG polymer chain (branched PEG) or more than one reactive functional group and a PEG polymer chain (forked PEG). The PEG reagent may contain a total PEG polymer of about 5, 10, 20, 40, 60, and 80 KDa.
[0133] In some embodiments, a thiol-reactive PEG can be used to react with a thiol group on at least one cysteine. For example, PEG-maleimide can be used, as well as PEG-orthopyridyl disulfide, PEG-vinyl sulfone, and PEG-iodoacetamide. In other embodiments, the thiol-reactive PEG can be a linear or branched structure with a single thiol-reactive moiety, or can be a forked structure with two or more reactive groups per PEG molecule.
[0134] There are many methods known in the art for PEGylating one or more cysteines in uricase, all of which can be used in the present invention.
[0135] In a preferred embodiment, the polymer is PEG, and the uricase conjugate of the present invention is a PEG-modified uricase, also referred to herein as PEG-uricase. PEG can be covalently attached via a cysteine residue present on the uricase. Preferably, the uricase has 1, 2, 3, 4 or 5 surface accessible cysteine residues at 1, 2, 3, 4 or 5 positions selected from positions 35, 82, 142, 194, 216, 287 and 288, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3, and the PEG is covalently attached via the cysteine residues at these positions. More preferably, the uricase comprises cysteine residues at two of the following positions: 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 194, or 82 and 287, respectively, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3, and the PEG is covalently attached via the cysteine residues at these positions.
[0136] In some embodiments, the amino acid sequence of the uricase is as shown in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19 or SEQ ID NO:20, and the PEG is covalently attached to the amino acid sequence through positions 142 and 216, 35 and 288, 35 and 142, 216 and 288, 35 and 288, 35 and 194, 82 and 287, 35 and 194, and 142 and 216 of the amino acid sequence, respectively, wherein the position numbers are relative to the position numbers of SEQ ID NO:3.
[0137] In some embodiments, the amino acid sequence of the uricase is as shown in SEQ ID NO: 17, and the PEG is covalently linked via cysteine residues 35 and 194, wherein the position numbers are relative to the position numbers of SEQ ID NO: 3.
[0138] Diseases and their treatment or prevention
[0139] The present invention also provides a method for treating or preventing hyperuricemia in mammalian body fluids or tissues using the uricase or uricase conjugate (such as PEG-uricase) of the present invention. The method generally comprises administering to a subject in need thereof an effective amount of the improved uricase or uricase conjugate (such as PEG-uricase) of any embodiment of the present invention, or a pharmaceutical composition containing the uricase or uricase conjugate (such as PEG-uricase). A suitable mode of administration may be selected according to actual conditions, including but not limited to oral, intravenous, subcutaneous, intramuscular, intra-arterial, by inhalation, and aerosol delivery.
[0140] The subject typically suffers from a disease associated with elevated uric acid, i.e., a disease that benefits from a reduction in uric acid. Typically, diseases associated with elevated uric acid include hyperuricemia, such as gout and tumor lysis syndrome.
[0141] Pharmaceutical preparations
[0142] The pharmaceutical composition of the present invention is a high-stability pharmaceutical composition containing uricase or uricase conjugate. The present invention finds that trehalose can significantly improve the stability of the pharmaceutical composition.
[0143] The pharmaceutical composition of the present invention is a liquid preparation with high stability. In particular, the present invention finds that the stability of the preparation containing phosphate buffer is significantly higher than that of other buffers.
[0144] The present invention provides a pharmaceutical composition comprising: (1) a buffer solution; and (2) the uricase or the uricase conjugate according to any embodiment of the present invention.
[0145] The uricase or uricase conjugate in the pharmaceutical composition of the present invention can be a uricase or a conjugate thereof comprising an amino acid sequence as shown in any one of SEQ ID NOs: 3-20, especially a PEG-modified uricase.
[0146] In the pharmaceutical composition of the present invention, the concentration of uricase or uricase conjugate is about 1-300 mg / mL, preferably about 1-250 mg / mL, preferably about 1-200 mg / mL, preferably about 5-80 mg / mL, more preferably 5-40 mg / mL; more preferably 5-20 mg / mL; more preferably, the above uricase concentration is about 5 mg / mL, 6 mg / mL, 7 mg / mL, 8 mg / mL, 9 mg / mL, 10 mg / mL, 12 mg / mL, 14 140 mg / mL, preferably about 8 mg / mL, 10 mg / mL or 20 mg / mL.
[0147] The buffer in the pharmaceutical composition of the present invention can be selected from phosphate buffer and Tris hydrochloric acid buffer to provide the pharmaceutical composition of the present invention with a pH of 6.0-8.5, preferably about 6.5-8.5, preferably about 7.0-8.5, preferably about 7.5-8.5, preferably about 7.5-8.1, and more preferably about 7.8. On the other hand, the pH of the buffer used in the pharmaceutical composition of the present invention can be 6.0-8.5, preferably about 6.5-8.5, preferably about 7.0-8.5, preferably about 7.5-8.5, preferably about 7.5-8.1, and more preferably about 7.8.
[0148] A particularly preferred buffer in the pharmaceutical composition of the present invention is a phosphate buffer. Preferably, the pH of the phosphate buffer is about 7.0 to about 8.5, preferably about 7.5-8.5, and more preferably about 7.5-8.1. Preferably, the phosphate buffer is a disodium hydrogen phosphate-sodium dihydrogen phosphate buffer. In some embodiments, the phosphate buffer is made of 1-30mM disodium hydrogen phosphate and 1-30mM sodium dihydrogen phosphate. In some embodiments, the phosphate buffer is made of 17mM disodium hydrogen phosphate and 3mM sodium dihydrogen phosphate monohydrate. In some embodiments, the phosphate buffer is made of 18.5mM disodium hydrogen phosphate and 1.5mM sodium dihydrogen phosphate monohydrate.
[0149] The buffer in the pharmaceutical composition of the present invention can be a Tris hydrochloric acid buffer. In some embodiments, the Tris hydrochloric acid buffer is made up of 1-30mM HCl and 1-30mM Tris (tris hydroxymethylaminomethane). In some embodiments, the Tris hydrochloric acid buffer is made up of 11.8mM Tris-HCl and 8.2mM Tris. In some embodiments, the Tris hydrochloric acid buffer is made up of 16.5mM Tris-HCl and 3.5mM Tris. In some embodiments, the Tris hydrochloric acid buffer is made up of 20mM Tris, adds concentrated hydrochloric acid to adjust pH to 7.5 or 8.0.
[0150] Therefore, in the pharmaceutical composition of the present invention, the buffer may be a phosphate buffer with a pH of 7.5-8.1, and its concentration in the pharmaceutical composition is 10-30 mM; and the pharmaceutical composition contains 5-40 mg / mL of the uricase or modified uricase described in any of the above embodiments, especially the PEG-modified uricase AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG described herein.
[0151] In some embodiments, the pharmaceutical composition of the present invention further contains a stabilizer. Preferably, the stabilizer is selected from one or more of arginine hydrochloride, sodium chloride, mannitol, sucrose and trehalose; preferably, the stabilizer is selected from mannitol, trehalose, a combination of mannitol and sodium chloride, or a combination of trehalose and sodium chloride; more preferably trehalose or a combination of trehalose and sodium chloride. The concentration of the stabilizer in the pharmaceutical composition of the present invention is about 10mM-400mM, preferably 20mM-300mM, more preferably 50mM-250mM. In some embodiments, the stabilizer is sodium chloride at a concentration of about 30-200mM, preferably 100-180; or the stabilizer is mannitol at a concentration of about 100-300mM, preferably 200-300mM; or the stabilizer is sucrose at a concentration of about 100-300mM, preferably 200-300mM; or the stabilizer is trehalose at a concentration of about 100-300mM, preferably 200-300mM; or the stabilizer is arginine hydrochloride at a concentration of about 30-200mM, preferably about 100-180mM. In some embodiments, the stabilizer is a combination of about 30-200mM sodium chloride and about 30-200mM mannitol, preferably about 30-100mM sodium chloride and about 100-180mM mannitol; or the stabilizer is a combination of about 30-200mM sodium chloride and about 30-200mM sucrose, preferably about 30-100mM sodium chloride and about 100-180mM sucrose; or the stabilizer is a combination of about 30-200mM sodium chloride and about 30-200mM trehalose, preferably about 30-100mM sodium chloride and about 100-180mM trehalose.
[0152] Therefore, in some embodiments, the pharmaceutical composition of the present invention contains: (a) 10-30 mM buffer, which is a phosphate buffer with a pH of 7.5-8.1; (b) 5-40 mg / mL of uricase or modified uricase described in any of the above embodiments, especially PEG-modified uricases AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG described herein; and (c) 20 mM-300 mM stabilizer, preferably mannitol at a concentration of about 200-300 mM, or about 200-300 mM trehalose, or a combination of about 30-100 mM sodium chloride and about 100-180 mM trehalose, or a combination of about 30-100 mM sodium chloride and about 100-180 mM mannitol. In some embodiments, the stabilizer is about 200-300 mM trehalose. In some embodiments, the stabilizer is a combination of about 30-100 mM sodium chloride and about 100-180 mM trehalose.
[0153] In some embodiments, the pharmaceutical composition of the present invention also includes a surfactant. Preferred surfactants are selected from polysorbate 80, polysorbate 20 and poloxamer 188. The most preferred surfactant is polysorbate 80. In w / v, the concentration of the surfactant in the pharmaceutical composition of the present invention is about 0.001%-0.1%, preferably about 0.02%-0.08%, preferably about 0.02%-0.04%. As a non-limiting example, the concentration of the surfactant in the pharmaceutical composition of the present invention is about 0.02%, 0.04% or 0.08%, preferably 0.02%.
[0154] Therefore, in some embodiments, the pharmaceutical composition of the present invention contains: a buffer, which is a phosphate buffer with a pH of 7.5-8.1, and its concentration in the pharmaceutical composition is 10-30 mM; 5-40 mg / mL of the uricase or modified uricase described in any of the above embodiments, especially the PEG-modified uricases AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG described herein; 100 mM-300 mM of a stabilizer, preferably, the stabilizer is a combination of about 30-100 mM sodium chloride and about 100-180 mM trehalose, or about 200-300 mM trehalose; and 0.02%-0.04% polysorbate 80 on a w / v basis.
[0155] The pharmaceutical composition of the present invention may be a liquid preparation or a lyophilized preparation.
[0156] Medical uses and methods
[0157] The present invention also provides the uricase or uricase conjugate or pharmaceutical composition according to any embodiment of the present invention for reducing the uric acid level in the body fluid and tissue of a mammal or treating or preventing hyperuricemia, the use of the uricase or uricase conjugate or pharmaceutical composition according to any embodiment of the present invention in the preparation of a medicament for reducing the uric acid level in the body fluid and tissue of a mammal or treating hyperuricemia, and the administration of a therapeutically effective amount of the uricase or uricase conjugate or pharmaceutical composition according to any embodiment of the present invention to an individual or patient in need thereof to reduce the uric acid level in the body fluid and tissue of a mammal or treat hyperuricemia.
[0158] The present invention will be described below in the form of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The following examples will use the following methods.
[0159] Protein content detection method
[0160] The protein concentration was measured using a UV spectrophotometer. The percent extinction coefficient (E1%) was set at 1.221 (g / ml)-1 cm- 1 . Use BIO MATE 3S instrument. Each sample was measured in parallel with 2 solutions, and each solution was measured 3 times, and the average value was taken. The concentration of the corresponding test sample was calculated by the extinction coefficient and OD value.
[0161] Size Exclusion Chromatography (SEC-HPLC) Purity Test Method
[0162] SEC-HPLC purity was tested by HPLC (Waters e2695 instrument) equipped with a SEC column (TOSOH G4000sxl SEC 7.8mm ID x 30cm, 8μm). The mobile phase composition was 50mM Tris, 150mM NaCl, pH 7.4. The relative percentages of the main peak, polymers and oligomers were calculated by area normalization. See the table below for details:
[0163] Chromatographic conditions Chromatographic parameters Detector wavelength 280nm Autosampler temperature 25±3℃ Column temperature 5±3℃ Flow rate 0.50ml / min Injection volume 25μl Operation Mode Isocratic mode Run time 30.00min
[0164] Reverse Phase High Performance Liquid Chromatography (RP-HPLC) Purity Test Method
[0165] RP-HPLC purity was tested by HPLC (Agilent 1260) equipped with a reverse phase column (Advancebio RP-mAb C4 4.6mm ID x150mm, 3.5μm). The mobile phase composition was phase A: 0.1% TFA aqueous solution; phase B: 0.1% TFA ACN. The relative percentages of the double PEG-modified protein peak, the single PEG-modified protein peak, and the naked protein were calculated by area normalization. See the table below for details:
[0166]
[0167]
[0168] Purity test method using non-reducing sodium dodecyl sulfate capillary electrophoresis (NR-CE-SDS)
[0169] NR-CE-SDS purity was detected by capillary electrophoresis (Maurice Instruments) equipped with a CE-SDS cassette. 95 μL of the test solution (1 mg / mL) was added with 5 μL of 0.8 M iodoacetamide, incubated at 70°C for 5 min for denaturation heat treatment, and detected by capillary electrophoresis (Maurice). The purity of the protein, single PEG-modified protein peak, and double PEG-modified protein peak were calculated as the percentage of the corrected peak area of the protein, single PEG-modified protein, and double PEG-modified protein to the sum of all corrected peak areas.
[0170] Enzyme activity detection method
[0171] The uric acid solution was diluted to 300 μM with buffer and 250 μL / well was added to Place the flat-bottomed black microplate in a Multi-Mode Microplate Reader pre-set to 30°C. After equilibration for 10 minutes, quickly transfer the sample diluted to 8.0 μg / mL to the microplate with uric acid solution at a volume of 50 μL / well. After shaking for 15 seconds, read the results every 2 minutes at 292 nm for a total of 20 minutes.
[0172] Buffer: 35.3 mM Tris base; 14.7 mM Tris HCl; 150 mM NaCl, 1.3 mM EDTA (ethylenediaminetetraacetic acid); 0.02% polysorbate 80; 220 mM sucrose, final pH 8.4 ± 0.2.
[0173] Unless otherwise specified, other methods and materials used in the examples are conventional methods and materials in the art.
[0174] Example
[0175] Example 1: Construction of uricase expression vector
[0176] The uricase nucleotide sequence was synthesized (Suzhou Jinweizhi Biotechnology Co., Ltd.) and constructed into the PET28a expression vector. The 5' restriction site of the target gene was NcoI, and the 3' restriction site was XhoI.
[0177] Taking the construction of AG-2C13 as an example, the nucleotide sequence after codon optimization is:
[0178] atgaccgcgaccgccgaaaccagcacgggtaccaaagttgttctgggccagaaccagtacggcaaagccgaagttcgtctggttaaggttacccgcaacacgtgccgccatgagattcaagatctgaatgtgaccagccagctccgcggcgatttcgaagccgcgcataccgccggtgataatgcccatgttgttgcgacggacacgcagaaaaacacggtttacgccttcgcccgcgatggtttcgcgaccaccgaagaatttctgctccgtctgggcaaacacttcaccgaaggttttgactgggttaccggtggtcgttgggccgcccagcagtttttctgggaccgcatcaacgaccacgaccacgcctttagccgcaataaaagcgaggtgcgtacggccgttctggaaatcagcggtagcgaacaagccatcgtggccggcattgaaggtctgaccgttctgaagagcaccggcagcgaatttcatggcttcccgcgcgacaagtacacgacgctgccagaaaccgaggatcgcattctggccaccgatgtgagtgcccgttggcgctataacacggtggaggtggatttcgatgccgtttacgcgagcgttcgcggtctgctgctgaaagcgtttgccgaaacccatagtctggcgctgcagcagaccatgtacgaaatgggtcgcgcggttatcgagacgcacccggaaatcgacgagatcaagatgagtctgccgaacaagcaccactttctggttgatctgagcccgttcggccaagataatccgaacgaggttttttacgcggccgatcgcccgtacggtctgatcgaggccaccatccagcgcgaaggctgctaa(SEQ ID NO:9).
[0179] Expression of uricase:
[0180] Through the transformation experiment of Escherichia coli BL21 (DE3) (Merck), the transformed monoclonal colony was picked on the LB / Kana plate. The Escherichia coli containing the uricase expression vector was cultured overnight at 37°C in 5ml of LB liquid medium (containing 50um / ml of kanamycin), and the above seed liquid was inoculated into a shaking flask containing 200ml of LB medium, with an inoculation ratio of 3% and cultured at 37°C. When the bacteria grew to OD 600 of 0.6-0.8, the culture temperature was reduced to 25°C. IPTG was added to a final concentration of 0.3mM to induce the expression of the target uricase protein.
[0181] Purification of uricase:
[0182] The bacteria are broken by high pressure homogenization or ultrasonic method, and after centrifugation, they are further purified by anion exchange method to obtain a protein with a purity of >95% for subsequent characterization analysis. The amino acid sequence of the protease is obtained by DNA sequencing.
[0183] Taking AG-00 as an example, it was verified that it was consistent with the optimized DNA sequence, and the amino acid sequence was SEQ ID NO: 1, as shown below:
[0184]
[0185] Synthesis of control uricase
[0186] A control uricase MEDI4945 was synthesized by a method similar to the above, and its amino acid sequence is SEQ ID NO: 2. MEDI4945 is a uricase disclosed in International Application No. PCT / US2016 / 032415, and its amino acid sequence is as follows:
[0187] MATAETSTGCKVVLGQNQYGKAEVRLVKVTRCTARHEIQDLNVTSQLSGDFEAAAHTAGDNAHVVATDTQKNTVYAFARDGFATTEEFLLRLGKHFTEGFDWVTGGRWAAQQFFWDRINDHDHAFSRNKSEVRTAVLEISGSEQAI VAGIEGLTVLKSTGSEFHGFPRDKYTTLQETTDRILATDVSARWRYNTVEVDFDAVYASVRGLLLKAFAETHSLALQQTMYEMGRAVIETHPEIDEIKMSLPNKHHFLVDLQPFGQDNPNEVFYAADRPYGLIEATIQREGSRAD
[0188] Example 2: Micrococcal uricase sequence evolution
[0189] A. Optimizing the C-terminus
[0190] SEQ ID NO: 1 was truncated by 5 amino acids at the C-terminus to eliminate the C-terminal Cys, thereby generating SEQ ID NO: 3. That is, DNA-specific primers were designed by a method similar to Example 1, and the AG-00 sequence was used as a template to delete the 298-302 amino acids at the C-terminus by PCR amplification, and the constructed product was verified by DNA sequencing. The obtained molecule was named: AG-00-1, and the sequence is shown below:
[0191]
[0192] B N-terminal amino acid substitution
[0193] Using a database of more than 15 aligned uricases, it was found that positions 1 to 17 in SEQ ID NO: 1 were not highly conserved with uricases of the same species. Therefore, specific primers were designed by a method similar to Example 1, and AG-00 was used as a template. The amino acid sequence (MTNIILGK) was used to replace the amino acids 1 to 17 of the AG-00 uricase molecule by PCR amplification, and the constructed product was verified by DNA sequencing to generate SEQ ID NO: 4. The molecule was named: AG-00-2, and the sequence is shown below:
[0194]
[0195] C. Site-directed mutagenesis
[0196] By the same method as in Example 1, DNA specific primers were designed based on the AG-00 sequence, and the 258th glutamine (Q) was mutated to serine (S) by bridge PCR technology, and the constructed product was verified by DNA sequencing to generate SEQ ID NO: 5, named AG-01, and the sequence is shown below:
[0197]
[0198] Using a similar method, glutamine (Q) at position 175 was mutated to proline (P), and threonine (T) at position 178 was mutated to glutamic acid (E), and the constructed product was verified by DNA sequencing to generate SEQ ID NO: 6, named AG-02, and the sequence is shown below:
[0199]
[0200] Using a similar method, glutamine (Q) at position 175 was mutated to proline (P), threonine (T) at position 178 was mutated to glutamic acid (E), and glutamine (Q) at position 258 was mutated to serine (S), and the constructed product was verified by DNA sequencing to generate SEQ ID NO: 7, named AG-05, the sequence of which is shown below:
[0201]
[0202] D. Optimize the N-terminus
[0203] It is known that when a protein is expressed in E. coli, the N-terminal methionine can be removed by Met aminopeptidase, depending on the size of the second amino acid residue after the methionine, if the second position is a small residue, typical cleavage occurs, if the second position is a bulky residue, no cleavage occurs, or if the second position residue is neither bulky nor particularly small, Met aminopeptidase may cleave part of it, thereby generating heterogeneity. Therefore, in order to eliminate the incomplete cleavage of the first amino acid caused by prokaryotic expression, the second threonine (T) in the amino acid sequence of SEQ ID NO: 4 was mutated to alanine (A), generating SEQ ID NO: 8, which was named AG-00-2A.
[0204] SEQ ID NO: 8
[0205]
[0206] E. Optimization of C-terminus and site-directed mutagenesis
[0207] By the same method as in Example 1, DNA specific primers were designed based on the AG-00 sequence, and the amino acids 298-302 at the C-terminus were deleted by PCR amplification, and the 175th glutamine (Q) was mutated to proline (P), the 178th threonine (T) was mutated to glutamic acid (E), and the 258th glutamine (Q) was mutated to serine (S). The constructed product was verified by DNA sequencing to generate SEQ ID NO: 9, named AG-1, and the sequence is shown below:
[0208] AG-1 (SEQ ID NO: 9)
[0209]
[0210] F. Further optimization of C-terminus and site-directed mutagenesis
[0211] By a method similar to Example 1, DNA specific primers were designed, and the AG-00 sequence was used as a template. The amino acids 288-301 (a total of 14 amino acids) at the C-terminus were deleted by PCR amplification to further streamline the protein structure and reduce the immunogenicity that may be caused by heterologous proteins. At the same time, the terminal Cys was retained as one of the subsequent PEG modification sites; the 175th glutamine (Q) was mutated to proline (P), the 178th threonine (T) was mutated to glutamic acid (E), and the 258th glutamine (Q) was mutated to serine (S). The constructed product was verified by DNA sequencing to generate SEQ ID NO: 10, named AG-2, and the sequence is shown below:
[0212] AG-2 (SEQ ID NO: 10)
[0213]
[0214]
[0215] G. Optimization of C / N-terminus and site-directed mutagenesis
[0216] By the same method as in Example 1, DNA specific primers were designed based on the AG-00 sequence, and the amino acids 298-302 at the C-terminus were deleted by PCR amplification, and the amino acids 1-17 of the AG-00 uricase molecule were replaced with the amino acid sequence MANIILGK, and the 175th glutamine (Q) was mutated to proline (P), the 178th threonine (T) was mutated to glutamic acid (E), and the 258th glutamine (Q) was mutated to serine (S). The constructed product was verified by DNA sequencing to generate SEQ ID NO: 11, named AG-3, and the sequence is shown below:
[0217] SEQ ID NO: 11
[0218]
[0219] H. Evaluation of the Enzymatic Activity of Modified Micrococcal Uricase
[0220] Using a Tris-HCl buffer system (pH 8.5), first add 0.25 mL of uric acid solution and 0.375 mL of Tris-HCl buffer to a test tube, keep it in a 37°C water bath for 10 min, add 0.125 mL of the above appropriately diluted uricase solution (0.004 mg / mL) to the test tube, react for 10 min, and then add 0.05 mL of 20% KOH to terminate the reaction. Determine the absorbance of the remaining uric acid at 292 nm to evaluate the enzyme activity of the modified Micrococcal uricase. The results are as follows: Figure 1 As shown, it can be seen that the introduction of point mutations did not affect the enzymatic activity of uricase.
[0221] The activity of urate oxidase is defined as: the amount of enzyme required to catalyze the decomposition of 1 μmol of uric acid per minute at 37°C and pH 8.5 is defined as 1 enzyme activity unit.
[0222] I. Evaluation of the Thermostability of Modified Micrococcal Uricase
[0223] The modified uricase molecule was placed in a water bath at 50°C, 60°C, and 70°C for 30 minutes. At 37°C, the molecule was balanced for 20 minutes, and then 20ul of 0.004mg / ml uricase solution was added and immediately read using a microplate reader. The reaction lasted for 10 minutes. The residual uricase activity was measured and the result was expressed as the absorbance difference. The uricase activity was normalized at 4°C. The result was as follows: Figure 2 Activity detection system: 50ul 800uM uric acid, 30ul buffer.
[0224] After AG-00 was heat treated at 60℃ for half an hour, the enzyme activity remained at 47%, while AG-01, AG-02 and AG-05 were treated under the same conditions, and the enzyme activity retention rates were 60%, 75% and 78% respectively. When treated at 70℃, the enzyme activity of AG-00 was maintained at 6%, and the enzyme activity retention rates of uricase AG-01, AG-02 and AG-05 were 17%, 20% and 15% respectively. It can be seen that the introduction of point mutations improves the thermal stability of enzyme activity.
[0225] J. Evaluation of Tm values of modified Micrococcal uricases
[0226] The Tm value of protein molecules was evaluated using the protein Thermo Shift assay kit. The above uricase was diluted to 0.5715 mg / mL with buffer (Na2HPO4 2.34 g / L; NaH2PO4·H2O 0.48 g / L; sucrose 75.31 g / L; Tween80 0.2 g / L; pH 7.6±2); the 1000× fluorescent dye in the kit was diluted to 8× fluorescent dye with ultrapure water; 70 μL of 0.5715 mg / mL uricase and 10 μL of 8× fluorescent dye were mixed evenly in a 1.5 mL EP tube and dispensed into 8-well PCR tubes or 96-well PCR plates, with a volume of 30 μL, for a total of 2 wells. There is also a blank control sample made by mixing 70 μL of preparation buffer and 10 μL of 8× fluorescent dye, and dispensed into 8-well PCR tubes or 96-well PCR plates, with a dispensing volume of 30 μL, and dispensed into 2 wells. There is also a system blank control made by mixing 70 μL of ultrapure water and 10 μL of 8× fluorescent dye, and dispensed into 8-well PCR tubes or 96-well PCR plates, with a dispensing volume of 30 μL, and dispensed into 2 wells.
[0227]
[0228] The results are shown in Table 1 below.
[0229] It can be seen that the Tm D values (the first protein denaturation temperature) of AG-01, AG-02, AG-05 and AG-00-2 are all higher than those of the wild-type uricase molecule AG-00 and the control MEDI4945. It can be seen that the introduction of point mutations improves the thermal stability of uricase.
[0230] Table 1
[0231] Serial number Sample name Tm D(℃) 1 MEDI4945 53.45 2 AG-00 58.12 3 AG-00-1 56.59 4 AG-00-2 61.91 5 AG-01 61.40 6 AG-02 58.92 7 AG-05 60.38
[0232] Example 3: Specific PEGylation
[0233] Therapeutic proteins modified with polyethylene glycol (PEG) can be randomly attached to selected protein residues (such as lysine side chains) or have specificity for characteristic sites. Specific PEGylation for a particular site can be better controlled and produce highly uniform PEGylated products with defined biological activity. Among the methods for site-specific attachment, the most widely used is coupling with unpaired cysteine residues, which requires the introduction of one or more free cysteine residues in the protein sequence. The C-terminally truncated AG-00-1 molecule sequence (SEQ ID NO: 3) does not contain cysteine, so cysteine can be introduced by amino acid mutation.
[0234] Cys mutation introduction
[0235] To select potential sites for the introduction of Cys residues in the AG-00-1 sequence, the following factors were considered:
[0236] (1) The site must be far away from the enzyme active site to avoid the risk of affecting activity;
[0237] (2) The sites should be close to each other to avoid steric hindrance that makes it difficult to PEGylate adjacent Cys;
[0238] (3) The site must be located on the protein surface to ensure effective reaction with thiol-reactive PEG reagents;
[0239] (4) The site must not be in a structural region or a conserved region.
[0240] After analysis, it was found that the sites that meet the above requirements include: A35, F82, S142, T194, E216, G287, and S288. Therefore, the above sites were selected as the sites for Cys mutation (the above sites are relative to SEQ ID NO: 3).
[0241] By adopting a method similar to Example 1, Cys mutations were introduced into AG-1, AG-2 and AG-3, respectively, to prepare the following molecules: AG-2C12, AG-2C13, AG-2C16, AG-2C17, AG-2C13-1, AG-2C01, AG-2C05-1, AG-2C01-1 and AG-2C12-1, whose amino acid sequences are shown in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19 or SEQ ID NO: 20, respectively.
[0242] Protein stability studies
[0243] Various improved uricases were placed in phosphate buffer, pH 7.0, 1 mM DTT, and 4°C. SEC-HPLC and RP-HPLC were used to compare the stability of each protein. The results are shown in the figure. Figure 3 shown.
[0244] RP-HPLC( Figure 3 , 3a) The results showed that AG-2C13, AG-2C13-1, AG-2C12, and AG-2C01-2 had good purity. SEC-HPLC( Figure 3 3b) The results showed that AG-2C13, AG-2C17, AG-2C12, and AG-2C01-2 had good purity. Based on the results of SEC-HPLC and RP-HPLC, AG-2C13, AG-2C12, and AG-2C01-2 were preferred.
[0245] PEGylation of Uricase
[0246] TCEP.HCl (0.5 mg, tris(2-carboxyethyl)phosphine hydrochloride) and M-MAL-PEG-10K (27.5 mg, maleimide polyethylene glycol, molecular weight 10000 Da) were added to 2 mg of uricase (100 mM PBS buffer, pH=7.0, 150 mM NaCl) in sequence, and reacted at room temperature for 2 hours. The reaction solution was purified by ion exchange chromatography to obtain PEGylated uricase.
[0247] Uricase activity determination method: using a phosphate buffer system (pH 7.3). The activity determination system refers to the above method (Example 2), and the absorbance value of the remaining uric acid at 292 nm is determined.
[0248] The Cys mutation sites selected above were combined in pairs and then subjected to PEGylation modification and uricase activity evaluation. The results are shown in Table 2.
[0249] Table 2
[0250] Molecule name Site mutation Sequence number Number of single subunits Enzyme activity maintenance Enzyme activity after modification U / mg AG-2C12 S142C / E216C 12 2 98% 2.0 AG-2C13 A35C / S288C 13 2 90% 1.95 AG-2C16 A35C / S142C 14 2 98% 1.69 AG-2C17 E216C / S288C 15 2 90% 1.85 AG-2C13-1 A35C / S288C 16 2 113% 2.33 AG-2C01-2 A35C / T194C 17 2 99% 1.55 AG-2C05-1 F82C / G287C 18 2 44% 0.67 AG-2C01-1 A35C / T194C 19 2 92% 1.43 AG-2C12-1 S142C / E216C 20 2 102% 1.65
[0251] *Note: AG-2C13-1, AG-2C01-1, and AG-2C12-1 also include the following mutations compared to AG-2C13, AG-2C01-2, and AG-2C12, respectively: S205D and G208R.
[0252] The two cysteines introduced in the molecules listed in Table 2 can be well modified by PEG, proving that the introduced sites are exposed on the surface of the molecules. And after the single subunit of uricase is double modified by mPEG, the enzyme activity retention rate ranges from 44% to 113%. In addition, the introduction of mutations at positions 205 and 208 can further improve the enzyme activity.
[0253] Example 4: Evaluation of PEGylated Uricase Activity
[0254] A. Study on the Enzyme Activity Kinetics of PEGylated Urokinase
[0255] Use Tris-HCl buffer system (pH 8.5), the stock solution of uricase working solution is 2mM uric acid, stored at 4℃. Enzyme activity determination process:
[0256] Set the temperature to 37 degrees, and the substrate (uric acid) concentration gradient: 600 micromolar, 500 micromolar, 400 micromolar, 200 micromolar, 100 micromolar, 50 micromolar, 25 micromolar, 12.5 micromolar; first add 50ul of the above uric acid solution and 30ul of the above Tris-HCl buffer to a 96-well plate, keep warm at 37℃ for 20min, and then quickly add 20ul of appropriately diluted uricase solution (0.004mg / mL) to the 96-well plate. Set the program: react for 10min, read the data every 20s, and start the reaction. The results are as follows: Figure 4 And as shown in Table 3.
[0257] Control uricase MEDI4945: uricase disclosed in International Application No. PCT / US2016 / 032415.
[0258] The results showed that the maximum reaction rates of uricase molecules were AG-2C01-2-PEG, AG-2C12-PEG, AG-2C13-PEG and MEDI4945, respectively.
[0259] Table 3
[0260] Molecule name Km Vmax Kcat AG-2C01-2-PEG 451.4 13.84 5.4 AG-2C12-PEG 355.5 13.24 5.3 AG-2C13-PEG 167.7 9.4 3.6 MEDI4945 101.5 6.8 2.6
[0261] Note: Km: Michaelis constant; Vmax: maximum reaction rate; Kcat: conversion number, which refers to the number of substrates converted by a single enzyme molecule in one second.
[0262] B. Accelerated stability assessment of PEG-modified urokinase (37°C)
[0263] The PEG-modified uricase was placed in a 37°C incubator with a phosphate buffer system at pH 7.0. Figure 5 As shown, it can be seen that at 37°C, the stability of AG-2C01-2-PEG is better than that of AG-2C12-PEG and AG-2C13-PEG.
[0264] Example 5: Pharmaceutical composition buffer system, pH and stabilizer screening experiment
[0265] In liquid pharmaceutical compositions, the buffer system and pH closely affect the stability of the antibody, and each antibody with unique physicochemical properties has the most suitable type of buffer and pH. This example aims to screen an optimal buffer system and pH so that the uricase disclosed in the present invention has the best stability for clinical application.
[0266] 5.1 Experimental procedures
[0267] This example was performed with uricase (AG-2C01-2-PEG) at a concentration of about 10 mg / mL and 20 mg / mL. The samples were prepared using Millipore Pellicon3 0.11 m 2 The membrane was ultrafiltration concentrated and the liquid was replaced. After the liquid was replaced, the sample was in the corresponding prescription and placed in a closed centrifuge tube for buffer screening. Phosphate buffer and Tris hydrochloric acid buffer were screened for buffers with pH values ranging from 7.5 to 8.0; sodium chloride, arginine hydrochloride, mannitol, sucrose and trehalose were screened for stabilizers for comparative testing (as shown in Table 4).
[0268] The samples were placed at 25±2℃ or 5±3℃, and taken out for analysis and testing at 0 weeks, 2 weeks, 4 weeks, 8 weeks (only 5±3℃) and 3 months (only 5±3℃). Evaluation indicators include: 1. Visual appearance; 2. Protein concentration (ultraviolet spectrophotometry); 3. SEC-HPLC (size exclusion chromatography) to determine the percentage of protein monomers, aggregation and fragments; 4. RP-HPLC (reverse phase high performance liquid chromatography) to determine protein purity; 5. NR-CE-SDS (non-reducing sodium dodecyl sulfate capillary electrophoresis) to detect protein purity; 6. Enzyme activity analysis. The effects of different buffer systems and pH on the stability of uricase were investigated, and the results are shown in Tables 5-1 to 5-6.
[0269] Table 4: Prescription information for buffer system, pH and stabilizer screening experiments
[0270]
[0271] 5.2 Experimental Results
[0272] 5.2.1 Appearance and protein content
[0273] According to the results in Table 5-1, the protein content of all samples did not show significant changes under accelerated conditions or long-term conditions.
[0274] According to the results in Table 5-2, no obvious visible foreign matter was found in all samples at T0, and no obvious opalescence. After being placed under accelerated conditions for 4 weeks, protein precipitation appeared in FS2-8 and FS2-3 prescriptions at a concentration of 20 mg / ml (FS2-8 was terminated for subsequent testing), and there were no significant changes in the other prescriptions; after being placed under long-term conditions for 3 months, protein precipitation appeared in FS2-8 at a concentration of 20 mg / ml and FS2-13 prescriptions, and there were no significant changes in the appearance of other samples.
[0275] Table 5-1: Protein content test data
[0276]
[0277] Note: “ / ” means: terminate the test.
[0278] Table 5-2: Appearance inspection data
[0279]
[0280] Note: “ / ” means: terminate the test.
[0281] 5.2.2 SEC purity
[0282] According to the SEC purity results in Table 5-3, the FS2-8 (20 mg / ml) group terminated the test; after 4 weeks of storage under accelerated conditions, the formulations containing arginine hydrochloride (FS2-2 and FS2-7) showed a significant increase in aggregates; after 3 months of storage under long-term conditions, all formulations did not show a significant decrease in SEC purity.
[0283] Table 5-3: SEC-HPLC monomer, aggregate and fragment content data
[0284]
[0285]
[0286]
[0287] Note: “ / ” means: terminate the test.
[0288] 5.2.3 RP-HPLC purity
[0289] According to the RP-HPLC purity results in Table 5-4, the FS2-8 (20 mg / ml) group was terminated from testing; after being placed under accelerated conditions for 4 weeks, the purity of the four groups FS2-2, FS2-7, FS2-12 and FS2-13 decreased at a faster rate; after being placed under long-term conditions for 3M, the purity of the four groups FS2-3 (10 / 20 mg / ml), FS2-4 and FS2-5 decreased at a slower rate.
[0290] Table 5-4: RP-HPLC protein purity screening data
[0291]
[0292]
[0293] Note: “ / ” means: terminate the test.
[0294] 5.2.4 NR-CE-SDS purity
[0295] According to the NR-CE-SDS purity results in Table 5-5, the FS2-8 (20 mg / ml) group terminated the test; after being placed under accelerated conditions for 4 weeks or under long-term conditions for 3M, all samples showed no significant change in purity.
[0296] Table 5-5: NR-CE-SDS purity screening data
[0297]
[0298] Note: “ / ” means: terminate the test.
[0299] 5.2.5 Enzyme activity
[0300] According to the enzyme activity results in Table 5-6, under accelerated or long-term conditions, all formulations except FS2-8 (20 mg / ml) showed no decrease in enzyme activity.
[0301] Table 5-6: Enzyme activity screening data
[0302]
[0303] Note: “ / ” means: terminate the test.
[0304] 5.3 Conclusion of the first round of prescription screening
[0305] From the results of protein content, enzyme activity and NR-CE-SDS purity, there was no significant difference among all the prescriptions. From the appearance, FS2-8 (20 mg / ml) had a poor appearance. From the results of SEC-HPLC, FS2-2 and FS2-7 showed an increase in aggregate peaks. From the results of RP-HPLC, the results of FS2-3 (10 / 20 mg / ml), FS2-4 and FS2-5 were better than the other groups.
[0306] In summary, the three prescriptions FS2-3, FS2-4 and FS2-5 are better. Therefore, 20mM phosphate buffer system (pH7.5) was selected as the buffer system for the next round of screening experiments; and the three stabilizers sucrose, trehalose and mannitol were further evaluated in the next round of experiments.
[0307] Example 6: Stabilizer and surfactant screening
[0308] 6.1 Experimental procedures
[0309] Uricase (AG-2C01-2-PEG) was purified by Millipore Pellicon3 0.11 m 2 The membrane was replaced with liquid. After the liquid was replaced, the sample was in the corresponding prescription. The final protein concentration was about 8 mg / ml (as shown in Table 6). It was aseptically filled into 2R vials (2.0 ml / bottle) for stability sampling and testing.
[0310] 1) Place the sample at 25±2℃ or 5±3℃, and take it out for analysis and testing at week 0, week 1, week 2, week 4, and week 8; 2) Perform 3 freeze-thaw cycles on the sample; 3) Shake the sample for 3 days. Evaluation indicators include: 1. Visual appearance; 2. Protein concentration (ultraviolet spectrophotometry); 3. SEC-HPLC (size exclusion chromatography) to determine the percentage of protein monomers, aggregations, and fragments; 4. RP-HPLC (reverse phase high performance liquid chromatography) to determine protein purity; 5. NR-CE-SDS (sodium dodecyl sulfate capillary electrophoresis) to detect protein purity; 6. Enzyme activity analysis. The results are shown in Tables 7-1 to 7-6.
[0311] Table 6: Stabilizer screening protocol
[0312]
[0313] Note: “ / ” means: not added.
[0314] 6.2 Experimental Results
[0315] 6.2.1 Appearance and protein concentration
[0316] According to the results in Tables 7-1 and 7-2, after being placed under accelerated conditions and long-term conditions for 8 weeks, the protein content of all samples did not change significantly; no obvious visible foreign matter was found in all samples at T0, and no obvious opalescence was found. After being placed under accelerated conditions or long-term conditions for 8 weeks, the four prescriptions of FS3-1, FS3-3, FS3-4 and FS3-6 did not change in appearance, and the remaining prescriptions showed increased opalescence; after 3 freeze-thaw cycles, no obvious visible foreign matter was found in the samples shaken for 3 days, and no obvious opalescence was found.
[0317] Table 7-1: Protein content screening data
[0318]
[0319] Note: “ / ” means: not tested.
[0320] Table 7-2: Appearance screening data
[0321]
[0322] Note: “ / ” means: not tested.
[0323] 6.2.2 SEC Purity
[0324] According to the SEC purity results in Table 7-3, all samples showed no significant change in SEC purity after being placed under accelerated conditions or long-term conditions for 8 weeks; and no significant change in SEC purity after 3 freeze-thaw cycles and 3 days of shaking.
[0325] Table 7-3: SEC-HPLC monomer, aggregate and fragment content data
[0326]
[0327]
[0328] Note: “ / ” means: not tested.
[0329] 6.2.3 RP-HPLC purity
[0330] According to the RP-HPLC purity results in Table 7-4, after being placed under accelerated conditions for 8 weeks, the purity of all samples decreased, but there was no difference between the groups; after being placed under long-term conditions for 8 weeks, there was no significant change in purity; after 3 freeze-thaw cycles and 3 days of shaking, there was no significant change in purity.
[0331] Table 7-4: RP-HPLC Purity Screening Data
[0332]
[0333] Note: “ / ” means: not tested.
[0334] 6.2.4 NR-CE-SDS purity
[0335] According to the NR-CE-SDS purity results in Table 7-5, after being placed under accelerated conditions for 8 weeks, the purity of all samples decreased, but there was no difference between the groups; after being placed under long-term conditions for 8 weeks, there was no significant change in purity.
[0336] Table 7-5: NR-CE-SDS purity screening data
[0337]
[0338] 6.2.5 Enzyme activity results
[0339] According to the enzyme activity results in Table 7-6, after being placed under accelerated conditions or long-term conditions for 8 weeks, all samples showed no significant changes in enzyme activity; after 3 freeze-thaw cycles and 3 days of shaking, no significant changes in enzyme activity were observed.
[0340] Table 7-6: Enzyme activity screening data
[0341]
[0342]
[0343] Note: “ / ” means: not tested.
[0344] 6.3 Conclusion of the Second Round of Prescription Screening
[0345] From the results of protein content, enzyme activity, NR-CE-SDS purity, SEC-HPLC purity and RP-HPLC purity, there was no significant difference among all the prescriptions. From the appearance results, the results of FS3-1, FS3-3, FS3-4 and FS3-6 were better.
[0346] In summary, FS3-1, FS3-3, FS3-4 and FS3-6 are the best prescriptions. Considering that mannitol is easy to form crystals when frozen and there is a risk of freeze-thaw, FS3-3 (20 mM phosphate, pH 7.5, containing 220 mM trehalose and 0.02% polysorbate 80) was selected as the preferred prescription.
[0347] Example 7: Compatibility stability test
[0348] 7.1 Experimental procedures
[0349] The stability of the six prescriptions FS3-1 to FS3-6 in Example 2 after dilution with 0.9% sodium chloride injection and 5% glucose injection was evaluated. Uricase (AG-2C01-2-PEG) was diluted to different concentrations of the corresponding medium (Table 8) according to the following scheme, and then placed at 25°C for 24 hours before testing to investigate different medium pairs.
[0350] Evaluation indicators include: 1. Visual appearance; 2. Protein concentration (ultraviolet spectrophotometry); 3. SEC-HPLC (size exclusion chromatography) to determine the percentage of protein monomers, aggregates and fragments. The results are shown in Table 9.
[0351] Table 8: Compatibility scheme
[0352]
[0353] 7.2 Experimental Results
[0354] The uricase of the present invention has good stability in the concentration range of 0.2mg / ml to 4mg / ml in 0.9% sodium chloride injection. In 5% glucose injection, the SEC fragment increases at a low concentration of 0.2mg / ml.
[0355] Table 9: Compatibility test results
[0356]
[0357] In summary, by investigating different buffer systems, different pH conditions, different protein concentrations and different excipient compositions, the stability of uricase was explored and studied, and the optimal liquid preparation formula was determined. According to the above experiments, the uricase of the present invention uses a phosphate buffer of pH 7.5 to adjust the pH, trehalose to adjust the osmotic pressure of the preparation, and polysorbate 80 to increase the solubility of the preparation.
[0358] The compatibility experiment showed that the final formulation of the uricase of the present invention was diluted with 0.9% sodium chloride injection and was left at room temperature for 24 hours without significant degradation within the protein concentration range of 0.2 to 4 mg / ml.
[0359] Considering that the isoelectric point of the uricase of the present invention is in the range of 5.5-6.3, and precipitation occurred at pH 7.0 in early preliminary experiments, the pH was finally increased to 7.8 to increase its solubility as far away from the pI as possible, and the pH range was 7.5-8.1.
[0360] Example 8: In vivo pharmacodynamics study
[0361] The effects of the test substances on serum uric acid levels were evaluated in a mouse model of hyperuricemia induced by intraperitoneal injection (ip) of exogenous uric acid by single intravenous (iv) administration. 120 normal mice (ICR-male) were randomly divided into 6 groups, 20 in each group. Groups 1 and 2 were given solvent as blank control and solvent control, respectively, group 3 was given MEDI4945 0.1 mg / kg as positive control, and groups 4, 5, and 6 were given 0.1 mg / kg doses of AG-2C13-PEG, AG-2C01-2-PEG, and AG-2C12-PEG (prescription FS3-3) as treatment groups, respectively. On the second day after administration, except for the blank control group, the experimental mice in the other groups were intraperitoneally injected with uric acid (250 mg / kg, 10 ml / kg) to establish the model. Blood samples were collected from animals 1 to 10 in each group at 30 minutes and 3 hours after modeling, and blood samples were collected from animals 11 to 20 at 1.5 hours and 6 hours after modeling.
[0362] The results are as follows Figure 6 As shown. The serum uric acid levels of animals in the AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG treatment groups at a dose of 0.1 mg / kg were significantly lower than those in the solvent control group at each time point from 0.5h to 6h after modeling (p<0.01). At 0.5h to 1.5h after modeling, the serum uric acid levels of animals in the three treatment groups were all below the detection limit (except for the AG-2C13-PEG group, which was 8.35μmol / l at 1.5h). At the tested dose (0.1mg / kg), a single injection of AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG significantly reduced the serum uric acid level in the hyperuricemia model of ICR mice induced by intraperitoneal injection of exogenous uric acid. At this dose, there was no significant difference in the effects of urokinase AG-2C13-PEG, AG-2C01-2-PEG and AG-2C12-PEG at each time point after modeling, but their efficacy was better than MEDI4945 after 3 hours. Sequence Listing <110> Shanghai Junshi Biopharmaceuticals Co., Ltd. Suzhou Junmeng Biopharmaceutical Technology Co., Ltd. <120> Uricase, its pharmaceutical composition and use thereof <130> 212407 <150> CN 202110381978.7 <151> 2021-04-09 <160> 20 <170> SIPOSequenceListing 1.0 <210> 1 <211> 302 <212> PRT <213> Artificial Sequence <400> 1 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Gln Glu 165 170 175 Thr Thr Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Gln Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn Ile Ala Gly Phe Cys 290 295 300 <210> 2 <211> 290 <212> PRT <213> Artificial Sequence <400> 2 Met Ala Thr Ala Glu Thr Ser Thr Gly Cys Lys Val Val Leu Gly Gln 1 5 10 15 Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg Cys 20 25 30 Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu Ser 35 40 45 Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val Val 50 55 60 Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp Gly 65 70 75 80 Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe Thr 85 90 95 Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln Phe 100 105 110 Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn Lys 115 120 125 Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln Ala 130 135 140 Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly Ser 145 150 155 160 Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Gln Glu Thr 165 170 175 Thr Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr Asn 180 185 190 Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly Leu 195 200 205 Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln Thr 210 215 220 Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile Asp 225 230 235 240 Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp Leu 245 250 255 Gln Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala Asp 260 265 270 Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser Arg 275 280 285 Ala Asp 290 <210> 3 <211> 297 <212> PRT <213> Artificial Sequence <400> 3 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Gln Glu 165 170 175 Thr Thr Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Gln Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295 <210> 4 <211> 288 <212> PRT <213> Artificial Sequence <400> 4 Met Thr Asn Ile Ile Leu Gly Lys Asn Gln Tyr Gly Lys Ala Glu Val 1 5 10 15 Arg Leu Val Lys Val Thr Arg Asn Thr Ala Arg His Glu Ile Gln Asp 20 25 30 Leu Asn Val Thr Ser Gln Leu Arg Gly Asp Phe Glu Ala Ala His Thr 35 40 45 Ala Gly Asp Asn Ala His Val Val Ala Thr Asp Thr Gln Lys Asn Thr 50 55 60 Val Tyr Ala Phe Ala Arg Asp Gly Phe Ala Thr Thr Glu Glu Phe Leu 65 70 75 80 Leu Arg Leu Gly Lys His Phe Thr Glu Gly Phe Asp Trp Val Thr Gly 85 90 95 Gly Arg Trp Ala Ala Gln Gln Phe Phe Trp Asp Arg Ile Asn Asp His 100 105 110 Asp His Ala Phe Ser Arg Asn Lys Ser Glu Val Arg Thr Ala Val Leu 115 120 125 Glu Ile Ser Gly Ser Glu Gln Ala Ile Val Ala Gly Ile Glu Gly Leu 130 135 140 Thr Val Leu Lys Ser Thr Gly Ser Glu Phe His Gly Phe Pro Arg Asp 145 150 155 160 Lys Tyr Thr Thr Leu Gln Glu Thr Thr Asp Arg Ile Leu Ala Thr Asp 165 170 175 Val Ser Ala Arg Trp Arg Tyr Asn Thr Val Glu Val Asp Phe Asp Ala 180 185 190 Val Tyr Ala Ser Val Arg Gly Leu Leu Leu Lys Ala Phe Ala Glu Thr 195 200 205 His Ser Leu Ala Leu Gln Gln Thr Met Tyr Glu Met Gly Arg Ala Val 210 215 220 Ile Glu Thr His Pro Glu Ile Asp Glu Ile Lys Met Ser Leu Pro Asn 225 230 235 240 Lys His His Phe Leu Val Asp Leu Gln Pro Phe Gly Gln Asp Asn Pro 245 250 255 Asn Glu Val Phe Tyr Ala Ala Asp Arg Pro Tyr Gly Leu Ile Glu Ala 260 265 270 Thr Ile Gln Arg Glu Gly Ser Arg Ala Asp His Pro Ile Trp Ser Asn 275 280 285 <210> 5 <211> 302 <212> PRT <213> Artificial Sequence <400> 5 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Gln Glu 165 170 175 Thr Thr Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn Ile Ala Gly Phe Cys 290 295 300 <210> 6 <211> 302 <212> PRT <213> Artificial Sequence <400> 6 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn Ile Ala Gly Phe Cys 290 295 300 <210> 7 <211> 302 <212> PRT <213> Artificial Sequence <400> 7 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn Ile Ala Gly Phe Cys 290 295 300 <210> 8 <211> 288 <212> PRT <213> Artificial Sequence <400> 8 Met Ala Asn Ile Ile Leu Gly Lys Asn Gln Tyr Gly Lys Ala Glu Val 1 5 10 15 Arg Leu Val Lys Val Thr Arg Asn Thr Ala Arg His Glu Ile Gln Asp 20 25 30 Leu Asn Val Thr Ser Gln Leu Arg Gly Asp Phe Glu Ala Ala His Thr 35 40 45 Ala Gly Asp Asn Ala His Val Val Ala Thr Asp Thr Gln Lys Asn Thr 50 55 60 Val Tyr Ala Phe Ala Arg Asp Gly Phe Ala Thr Thr Glu Glu Phe Leu 65 70 75 80 Leu Arg Leu Gly Lys His Phe Thr Glu Gly Phe Asp Trp Val Thr Gly 85 90 95 Gly Arg Trp Ala Ala Gln Gln Phe Phe Trp Asp Arg Ile Asn Asp His 100 105 110 Asp His Ala Phe Ser Arg Asn Lys Ser Glu Val Arg Thr Ala Val Leu 115 120 125 Glu Ile Ser Gly Ser Glu Gln Ala Ile Val Ala Gly Ile Glu Gly Leu 130 135 140 Thr Val Leu Lys Ser Thr Gly Ser Glu Phe His Gly Phe Pro Arg Asp 145 150 155 160 Lys Tyr Thr Thr Leu Gln Glu Thr Thr Asp Arg Ile Leu Ala Thr Asp 165 170 175 Val Ser Ala Arg Trp Arg Tyr Asn Thr Val Glu Val Asp Phe Asp Ala 180 185 190 Val Tyr Ala Ser Val Arg Gly Leu Leu Leu Lys Ala Phe Ala Glu Thr 195 200 205 His Ser Leu Ala Leu Gln Gln Thr Met Tyr Glu Met Gly Arg Ala Val 210 215 220 Ile Glu Thr His Pro Glu Ile Asp Glu Ile Lys Met Ser Leu Pro Asn 225 230 235 240 Lys His His Phe Leu Val Asp Leu Gln Pro Phe Gly Gln Asp Asn Pro 245 250 255 Asn Glu Val Phe Tyr Ala Ala Asp Arg Pro Tyr Gly Leu Ile Glu Ala 260 265 270 Thr Ile Gln Arg Glu Gly Ser Arg Ala Asp His Pro Ile Trp Ser Asn 275 280 285 <210> 9 <211> 297 <212> PRT <213> Artificial Sequence <400> 9 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295 <210> 10 <211> 288 <212> PRT <213> Artificial Sequence <400> 10 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Cys 275 280 285 <210> 11 <211> 288 <212> PRT <213> Artificial Sequence <400> 11 Met Ala Asn Ile Ile Leu Gly Lys Asn Gln Tyr Gly Lys Ala Glu Val 1 5 10 15 Arg Leu Val Lys Val Thr Arg Asn Thr Ala Arg His Glu Ile Gln Asp 20 25 30 Leu Asn Val Thr Ser Gln Leu Arg Gly Asp Phe Glu Ala Ala His Thr 35 40 45 Ala Gly Asp Asn Ala His Val Val Ala Thr Asp Thr Gln Lys Asn Thr 50 55 60 Val Tyr Ala Phe Ala Arg Asp Gly Phe Ala Thr Thr Glu Glu Phe Leu 65 70 75 80 Leu Arg Leu Gly Lys His Phe Thr Glu Gly Phe Asp Trp Val Thr Gly 85 90 95 Gly Arg Trp Ala Ala Gln Gln Phe Phe Trp Asp Arg Ile Asn Asp His 100 105 110 Asp His Ala Phe Ser Arg Asn Lys Ser Glu Val Arg Thr Ala Val Leu 115 120 125 Glu Ile Ser Gly Ser Glu Gln Ala Ile Val Ala Gly Ile Glu Gly Leu 130 135 140 Thr Val Leu Lys Ser Thr Gly Ser Glu Phe His Gly Phe Pro Arg Asp 145 150 155 160 Lys Tyr Thr Thr Leu Pro Glu Thr Glu Asp Arg Ile Leu Ala Thr Asp 165 170 175 Val Ser Ala Arg Trp Arg Tyr Asn Thr Val Glu Val Asp Phe Asp Ala 180 185 190 Val Tyr Ala Ser Val Arg Gly Leu Leu Leu Lys Ala Phe Ala Glu Thr 195 200 205 His Ser Leu Ala Leu Gln Gln Thr Met Tyr Glu Met Gly Arg Ala Val 210 215 220 Ile Glu Thr His Pro Glu Ile Asp Glu Ile Lys Met Ser Leu Pro Asn 225 230 235 240 Lys His His Phe Leu Val Asp Leu Ser Pro Phe Gly Gln Asp Asn Pro 245 250 255 Asn Glu Val Phe Tyr Ala Ala Asp Arg Pro Tyr Gly Leu Ile Glu Ala 260 265 270 Thr Ile Gln Arg Glu Gly Ser Arg Ala Asp His Pro Ile Trp Ser Asn 275 280 285 <210> 12 <211> 297 <212> PRT <213> Artificial Sequence <400> 12 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Cys Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Cys Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295 <210> 13 <211> 288 <212> PRT <213> Artificial Sequence <400> 13 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Cys Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Cys 275 280 285 <210> 14 <211> 297 <212> PRT <213> Artificial Sequence <400> 14 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Cys Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Cys Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295 <210> 15 <211> 288 <212> PRT <213> Artificial Sequence <400> 15 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Cys Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Cys 275 280 285 <210> 16 <211> 288 <212> PRT <213> Artificial Sequence <400> 16 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Cys Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Asp Val Arg Arg 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Cys 275 280 285 <210> 17 <211> 288 <212> PRT <213> Artificial Sequence <400> 17 Met Ala Asn Ile Ile Leu Gly Lys Asn Gln Tyr Gly Lys Ala Glu Val 1 5 10 15 Arg Leu Val Lys Val Thr Arg Asn Thr Cys Arg His Glu Ile Gln Asp 20 25 30 Leu Asn Val Thr Ser Gln Leu Arg Gly Asp Phe Glu Ala Ala His Thr 35 40 45 Ala Gly Asp Asn Ala His Val Val Ala Thr Asp Thr Gln Lys Asn Thr 50 55 60 Val Tyr Ala Phe Ala Arg Asp Gly Phe Ala Thr Thr Glu Glu Phe Leu 65 70 75 80 Leu Arg Leu Gly Lys His Phe Thr Glu Gly Phe Asp Trp Val Thr Gly 85 90 95 Gly Arg Trp Ala Ala Gln Gln Phe Phe Trp Asp Arg Ile Asn Asp His 100 105 110 Asp His Ala Phe Ser Arg Asn Lys Ser Glu Val Arg Thr Ala Val Leu 115 120 125 Glu Ile Ser Gly Ser Glu Gln Ala Ile Val Ala Gly Ile Glu Gly Leu 130 135 140 Thr Val Leu Lys Ser Thr Gly Ser Glu Phe His Gly Phe Pro Arg Asp 145 150 155 160 Lys Tyr Thr Thr Leu Pro Glu Thr Glu Asp Arg Ile Leu Ala Thr Asp 165 170 175 Val Ser Ala Arg Trp Arg Tyr Asn Cys Val Glu Val Asp Phe Asp Ala 180 185 190 Val Tyr Ala Ser Val Arg Gly Leu Leu Leu Lys Ala Phe Ala Glu Thr 195 200 205 His Ser Leu Ala Leu Gln Gln Thr Met Tyr Glu Met Gly Arg Ala Val 210 215 220 Ile Glu Thr His Pro Glu Ile Asp Glu Ile Lys Met Ser Leu Pro Asn 225 230 235 240 Lys His His Phe Leu Val Asp Leu Ser Pro Phe Gly Gln Asp Asn Pro 245 250 255 Asn Glu Val Phe Tyr Ala Ala Asp Arg Pro Tyr Gly Leu Ile Glu Ala 260 265 270 Thr Ile Gln Arg Glu Gly Ser Arg Ala Asp His Pro Ile Trp Ser Asn 275 280 285 <210> 18 <211> 297 <212> PRT <213> Artificial Sequence <400> 18 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Cys Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Ser Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Ser Val Arg Gly 195 200 205 Leu Leu Leu Lys Ala Phe Ala Glu Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Cys Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295 <210> 19 <211> 288 <212> PRT <213> Artificial Sequence <400> 19 Met Ala Asn Ile Ile Leu Gly Lys Asn Gln Tyr Gly Lys Ala Glu Val 1 5 10 15 Arg Leu Val Lys Val Thr Arg Asn Thr Cys Arg His Glu Ile Gln Asp 20 25 30 Leu Asn Val Thr Ser Gln Leu Arg Gly Asp Phe Glu Ala Ala His Thr 35 40 45 Ala Gly Asp Asn Ala His Val Val Ala Thr Asp Thr Gln Lys Asn Thr 50 55 60 Val Tyr Ala Phe Ala Arg Asp Gly Phe Ala Thr Thr Glu Glu Phe Leu 65 70 75 80 Leu Arg Leu Gly Lys His Phe Thr Glu Gly Phe Asp Trp Val Thr Gly 85 90 95 Gly Arg Trp Ala Ala Gln Gln Phe Phe Trp Asp Arg Ile Asn Asp His 100 105 110 Asp His Ala Phe Ser Arg Asn Lys Ser Glu Val Arg Thr Ala Val Leu 115 120 125 Glu Ile Ser Gly Ser Glu Gln Ala Ile Val Ala Gly Ile Glu Gly Leu 130 135 140 Thr Val Leu Lys Ser Thr Gly Ser Glu Phe His Gly Phe Pro Arg Asp 145 150 155 160 Lys Tyr Thr Thr Leu Pro Glu Thr Glu Asp Arg Ile Leu Ala Thr Asp 165 170 175 Val Ser Ala Arg Trp Arg Tyr Asn Cys Val Glu Val Asp Phe Asp Ala 180 185 190 Val Tyr Ala Asp Val Arg Arg Leu Leu Leu Lys Ala Phe Ala Glu Thr 195 200 205 His Ser Leu Ala Leu Gln Gln Thr Met Tyr Glu Met Gly Arg Ala Val 210 215 220 Ile Glu Thr His Pro Glu Ile Asp Glu Ile Lys Met Ser Leu Pro Asn 225 230 235 240 Lys His His Phe Leu Val Asp Leu Ser Pro Phe Gly Gln Asp Asn Pro 245 250 255 Asn Glu Val Phe Tyr Ala Ala Asp Arg Pro Tyr Gly Leu Ile Glu Ala 260 265 270 Thr Ile Gln Arg Glu Gly Ser Arg Ala Asp His Pro Ile Trp Ser Asn 275 280 285 <210> 20 <211> 297 <212> PRT <213> Artificial Sequence <400> 20 Met Thr Ala Thr Ala Glu Thr Ser Thr Gly Thr Lys Val Val Leu Gly 1 5 10 15 Gln Asn Gln Tyr Gly Lys Ala Glu Val Arg Leu Val Lys Val Thr Arg 20 25 30 Asn Thr Ala Arg His Glu Ile Gln Asp Leu Asn Val Thr Ser Gln Leu 35 40 45 Arg Gly Asp Phe Glu Ala Ala His Thr Ala Gly Asp Asn Ala His Val 50 55 60 Val Ala Thr Asp Thr Gln Lys Asn Thr Val Tyr Ala Phe Ala Arg Asp 65 70 75 80 Gly Phe Ala Thr Thr Glu Glu Phe Leu Leu Arg Leu Gly Lys His Phe 85 90 95 Thr Glu Gly Phe Asp Trp Val Thr Gly Gly Arg Trp Ala Ala Gln Gln 100 105 110 Phe Phe Trp Asp Arg Ile Asn Asp His Asp His Ala Phe Ser Arg Asn 115 120 125 Lys Ser Glu Val Arg Thr Ala Val Leu Glu Ile Ser Gly Cys Glu Gln 130 135 140 Ala Ile Val Ala Gly Ile Glu Gly Leu Thr Val Leu Lys Ser Thr Gly 145 150 155 160 Ser Glu Phe His Gly Phe Pro Arg Asp Lys Tyr Thr Thr Leu Pro Glu 165 170 175 Thr Glu Asp Arg Ile Leu Ala Thr Asp Val Ser Ala Arg Trp Arg Tyr 180 185 190 Asn Thr Val Glu Val Asp Phe Asp Ala Val Tyr Ala Asp Val Arg Arg 195 200 205 Leu Leu Leu Lys Ala Phe Ala Cys Thr His Ser Leu Ala Leu Gln Gln 210 215 220 Thr Met Tyr Glu Met Gly Arg Ala Val Ile Glu Thr His Pro Glu Ile 225 230 235 240 Asp Glu Ile Lys Met Ser Leu Pro Asn Lys His His Phe Leu Val Asp 245 250 255 Leu Ser Pro Phe Gly Gln Asp Asn Pro Asn Glu Val Phe Tyr Ala Ala 260 265 270 Asp Arg Pro Tyr Gly Leu Ile Glu Ala Thr Ile Gln Arg Glu Gly Ser 275 280 285 Arg Ala Asp His Pro Ile Trp Ser Asn 290 295
Claims
1. A uricase, the amino acid sequence of which is: (1) compared with the amino acid sequence shown in SEQ ID NO: 9, cysteine residues are introduced at positions 35 and 142 or at positions 142 and 216, and optionally have S205D and G208R substitution mutations; (2) compared with the amino acid sequence of SEQ ID NO: 10, cysteine residues are introduced at positions 35 and 288 or at positions 216 and 288, and optionally have S205D and G208R substitution mutations; or (3) compared with the amino acid sequence shown in SEQ ID NO: 11, cysteine residues are introduced at positions 35 and 194, and optionally have S205D and G208R substitution mutations; in, The position number is relative to the position number of SEQ ID NO: 3; and the uricase does not include the uricase whose amino acid sequence is shown in SEQ ID NO:
13.
2. The uricase according to claim 1, wherein the amino acid sequence of the uricase is shown in SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19 or SEQ ID NO:
20.
3. A uricase whose amino acid sequence is selected from the following sequences (1) to (8): (1) TATAETSTG TKVVLGQNQY GKAAEVRLVKV TRNTARHEIQ DLNVTSQLRG DFEAAHTAGD NAHVVATDTQ KNTVYAFARDGFATTEEFLL RLGKHFTEGF DWVTGGRWAA QQFFWDRIND HDHAFSRNKS EVRTAVLEIS G C EQAIVAGI EGLTVLKSTG SEFHGFPRDK YTTL P ET E DR ILATDVSARW RYNTVEVDFD AVYASVRGLL LKAFA C THSL ALQQTMYEMG RAVIETHPEI DEIKMSLPNK HHFLVDL S PF GQDNPNEVFY AADRPYGLIE ATIQREGSRA DHPIWSN; (2) TATAETSTG TKVVLGQNQY GKAEVRLVKV TRNT<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> RHEIQ DLNVTSQLRG DFEAAHTAGD<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> NAHVVATDTQ KNTVYAFARD GFATTEEFLL RLGKHFTEGF DWVTGGRWAA QQFFWDRIND<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> HDHAFSRNKS EVRTAVLEIS G<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> EQAIVAGI EGLTVLKSTG SEFHGFPRDK YTTL<h2 style=";text-align:left;direction:ltr"> P <h2 style=";text-align:left;direction:ltr"> ET<h2 style=";text-align:left;direction:ltr"> E <h2 style=";text-align:left;direction:ltr"> DR<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ILATDVSARW RYNTVEVDFD AVYASVRGLL LKAFAETHSL ALQQTMYEMG RAVIETHPEI<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> DEIKMSLPNK HHFLVDL<h2 style=";text-align:left;direction:ltr"> S <h2 style=";text-align:left;direction:ltr"> PF GQDNPNEVFY AADRPYGLIE ATIQREGSRA DHPIWSN;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (3)TATAETSTG TKVVLGQNQY GKAEVRLVKV TRNTARHEIQ DLNVTSQLRG DFEAAHTAGD<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> NAHVVATDTQ KNTVYAFARD GFATTEEFLL RLGKHFTEGF DWVTGGRWAA QQFFWDRIND<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> HDHAFSRNKS EVRTAVLEIS GSEQAIVAGI EGLTVLKSTG SEFHGFPRDK YTTL<h2 style=";text-align:left;direction:ltr"> P <h2 style=";text-align:left;direction:ltr"> ET<h2 style=";text-align:left;direction:ltr"> E <h2 style=";text-align:left;direction:ltr"> DR<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ILATDVSARW RYNTVEVDFD AVYASVRGLL LKAFA<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> THSL ALQQTMYEMG RAVIETHPEI<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> DEIKMSLPNK HHFLVDL<h2 style=";text-align:left;direction:ltr"> S <h2 style=";text-align:left;direction:ltr"> PF GQDNPNEVFY AADRPYGLIE ATIQREG<h2 style=";text-align:left;direction:ltr"> C; <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (4)TATAETSTG TKVVLGQNQY GKAEVRLVKV TRNT<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> RHEIQ DLNVTSQLRG DFEAAHTAGD<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">NAHVVATDTQ KNTVYAFARD GFATTEEFLL RLGKHFTEGF DWVTGGRWAA QQFFWDRIND<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> HDHAFSRNKS EVRTAVLEIS GSEQAIVAGI EGLTVLKSTG SEFHGFPRDK YTTL<h2 style=";text-align:left;direction:ltr"> P <h2 style=";text-align:left;direction:ltr"> ET<h2 style=";text-align:left;direction:ltr"> E <h2 style=";text-align:left;direction:ltr"> DR<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ILATDVSARW RYNTVEVDFD AVYADVRRLL LKAFAETHSL ALQQTMYEMG RAVIETHPEI<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> DEIKMSLPNK HHFLVDL<h2 style=";text-align:left;direction:ltr"> S <h2 style=";text-align:left;direction:ltr"> PF GQDNPNEVFY AADRPYGLIE ATIQREG<h2 style=";text-align:left;direction:ltr"> C; <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (5)ANIILGKNQ YGKAEVRLVK VTRNT<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> RHEI QDLNVTSQLR GDFEAAHTAG DNAHVVATDT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> QKNTVYAFAR DGFATTEEFL LRLGKHFTEG FDWVTGGRWA AQQFFWDRIN DHDHAFSRNK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SEVRTAVLEI SGSEQAIVAG IEGLTVLKST GSEFHGFPRD KYTTL<h2 style=";text-align:left;direction:ltr"> P <h2 style=";text-align:left;direction:ltr"> ET<h2 style=";text-align:left;direction:ltr"> E <h2 style=";text-align:left;direction:ltr"> D RILATDVSAR<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> WRYN<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> VEVDF DAVYASVRGL LLKAFAETHS LALQQTMYEM GRAVIETHPE IDEIKMSLPN<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> KHHFLVDL<h2 style=";text-align:left;direction:ltr"> S <h2 style=";text-align:left;direction:ltr"> P FGQDNPNEVF YAADRPYGLI EATIQREGSR ADHPIWSN;<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> (6)ANIILGKNQ YGKAEVRLVK VTRNT<h2 style=";text-align:left;direction:ltr"> C <h2 style=";text-align:left;direction:ltr"> RHEI QDLNVTSQLR GDFEAAHTAG DNAHVVATDT<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> QKNTVYAFAR DGFATTEEFL LRLGKHFTEG FDWVTGGRWA AQQFFWDRIN DHDHAFSRNK<h2 style=";text-align:left;direction:ltr"> SEVRTAVLEISGSEQAIVAG IEGLTVLKSTGSEFHGFPRDKYTTL P ET E D RILATDVSAR WRYN C VEVDF DAVYA D VR R L LLKAFAETHS LALQQTMYEM GRAVIETHPE IDEIKMSLPN KHHFLVDL S P FGQDNPNEVF YAADRPYGLI EATIQREGSR ADHPIWSN; or (7) TATAETSTG TKVVLGQNQY GKAAEVRLVKV TRNTARHEIQ DLNVTSQLRG DFEAAHTAGD NAHVVATDTQ KNTVYAFARDGFATTEEFLL RLGKHFTEGF DWVTGGRWAA QQFFWDRIND HDHAFSRNKS EVRTAVLEIS G C EQAIVAGI EGLTVLKSTG SEFHGFPRDK YTTL P ET E DR ILATDVSARW RYNTVEVDFD AVYA D VR R LL LKAFA C THSL ALQQTMYEMG RAVIETHPEI DEIKMSLPNK HHFLVDL S PF GQDNPNEVFY AADRPYGLIE ATIQREGSRA DHPIWSN. 4 . A modified uricase, wherein the modified uricase is the uricase according to any one of claims 1 to 3 modified with polyethylene glycol (PEG).
5. The modified uricase of claim 4, wherein the PEG is covalently linked to the N-terminus and / or C-terminus of the uricase, and / or is covalently linked via a cysteine residue present on the uricase.
6. A pharmaceutical composition comprising: (1) buffer; and (2) The uricase according to any one of claims 1 to 3 or the modified uricase according to claim 4 or 5.
7. The pharmaceutical composition of claim 6, wherein the buffer is selected from the group consisting of phosphate buffer, Tris-HCl buffer, citrate buffer and histidine buffer.
8. The pharmaceutical composition of claim 6, wherein the buffer is phosphate buffer or Tris-HCl buffer.
9. The pharmaceutical composition of claim 6, wherein the buffer is disodium hydrogen phosphate-sodium dihydrogen phosphate buffer.
10. The pharmaceutical composition of claim 6, wherein the concentration of the buffer is 10-50 mM.
11. The pharmaceutical composition of claim 10, wherein the concentration of the buffer is 10-30 mM.
12. The pharmaceutical composition of claim 6, wherein the pH of the buffer is 6.0-8.
5.
13. The pharmaceutical composition of claim 6, wherein the pH of the buffer is 7.0-8.
5.
14. The pharmaceutical composition of claim 6, wherein the pH of the buffer is 7.5 to 8.
1.
15. The pharmaceutical composition according to any one of claims 6 to 14, wherein the pharmaceutical composition further comprises a stabilizer, and the stabilizer is selected from one or more of arginine hydrochloride, sodium chloride, mannitol, sucrose and trehalose.
16. The pharmaceutical composition of claim 15, wherein the stabilizer is selected from mannitol, trehalose, a combination of mannitol and sodium chloride, or a combination of trehalose and sodium chloride.
17. The pharmaceutical composition of claim 15, wherein the concentration of the stabilizer is 20 mM-300 mM.
18. The pharmaceutical composition of claim 17, wherein the concentration of the stabilizer is 50 mM-250 mM.
19. The pharmaceutical composition of claim 15, wherein the stabilizer is sodium chloride at a concentration of 30-200 mM; or the stabilizer is arginine hydrochloride at a concentration of 30-200 mM; or the stabilizer is mannitol at a concentration of 100-300 mM; or the stabilizer is sucrose at a concentration of 100-300 mM; or the stabilizer is trehalose at a concentration of 100-300 mM; or the stabilizer is a combination of sodium chloride at 30-200 mM and mannitol at 30-200 mM; or the stabilizer is a combination of sodium chloride at 30-200 mM and trehalose at 30-200 mM; or the stabilizer is a combination of sodium chloride at 30-200 mM and sucrose at 30-200 mM.
20. The pharmaceutical composition of claim 15, wherein the stabilizer is 100-300 mM trehalose, 100-300 mM mannitol, a combination of 30-200 mM sodium chloride and 30-200 mM mannitol, or a combination of 30-200 mM sodium chloride and 30-200 mM trehalose.
21. The pharmaceutical composition of claim 15, wherein the stabilizer is 100-300 mM trehalose or a combination of 30-200 mM sodium chloride and 30-200 mM trehalose.
22. The pharmaceutical composition according to any one of claims 6 to 14, wherein the pharmaceutical composition further comprises a surfactant selected from polysorbate 80, polysorbate 20 or poloxamer 188.
23. The pharmaceutical composition of claim 22, wherein the surfactant is polysorbate 80.
24. The pharmaceutical composition of claim 22, wherein the surfactant concentration is 0.01%-0.1%.
25. The pharmaceutical composition of claim 24, wherein the surfactant concentration is 0.02%-0.08%.
26. The pharmaceutical composition of claim 25, wherein the surfactant concentration is 0.02%-0.05%.
27. The pharmaceutical composition of claim 6, wherein the concentration of the uricase or modified uricase is 1-200 mg / mL.
28. The pharmaceutical composition of claim 27, wherein the concentration of the uricase or modified uricase is 5-80 mg / mL.
29. The pharmaceutical composition of claim 27, wherein the concentration of the uricase or modified uricase is 5-40 mg / mL.
30. The pharmaceutical composition according to claim 6, comprising the components shown in any one of the following (1)-(5): (1) (a) 5 mg / mL to 40 mg / mL uricase or modified uricase; (b) 10 to 30 mM phosphate buffer, pH 7.5 to 8.1; (c) 100 to 300 mM mannitol; and (d) 0.01% to 0.1% polysorbate 80; or (2) (a) 5 mg / mL to 40 mg / mL uricase or modified uricase; (b) 10-30 mM Tris-HCl buffer, pH 7.5-8.1; (c) 100-300 mM trehalose; and (d) 0.01% to 0.1% polysorbate 80; or (3) (a) 5 mg / mL to 40 mg / mL uricase or modified uricase; (b) 10-30 mM phosphate buffer, pH 7.5-8.1; (c) 100-300 mM trehalose; and (d) 0.01% to 0.1% polysorbate 80; or (4) (a) 5 mg / mL to 40 mg / mL of uricase or modified uricase; (b) 10-30 mM phosphate buffer, pH 7.5-8.1; (c) a combination of 30-200 mM sodium chloride and 30-200 mM mannitol; and (d) 0.01% to 0.1% polysorbate 80; or (5) (a) 5 mg / mL-40 mg / mL uricase or modified uricase; (b) 10-30 mM phosphate buffer, pH 7.5-8.1; (c) a combination of 30-200 mM sodium chloride and 30-200 mM trehalose; and (d) 0.01%-0.1% polysorbate 80.
31. The pharmaceutical composition according to claim 30, comprising the components shown in any one of the following (1)-(5): (1) (a) 8 mg / mL uricase or modified uricase; (b) 20 mM phosphate buffer, pH 7.5-7.8; (c) 240 mM mannitol; and (d) 0.02% polysorbate 80; or (2) (a) 8 mg / mL uricase or modified uricase; (b) 20 mM Tris-HCl buffer, pH 7.5-8.0; (c) 220 mM trehalose; and (d) 0.02% polysorbate 80; or (3) (a) 8 mg / mL uricase or modified uricase; (b) 20 mM phosphate buffer, pH 7.5-7.8; (c) 220 mM trehalose; and (d) 0.02% polysorbate 80; or (4) (a) 8 mg / mL uricase or modified uricase; (b) 20 mM phosphate buffer, pH 7.5-7.8; (c) a combination of 50 mM sodium chloride and 140 mM mannitol; and (d) 0.02% polysorbate 80; or (5) (a) 8 mg / mL uricase or modified uricase; (b) 20 mM phosphate buffer, pH 7.5-7.8; (c) a combination of 50 mM sodium chloride and 140 mM trehalose; and (d) 0.02% polysorbate 80.
32. An injection comprising the pharmaceutical composition according to any one of claims 6 to 31 and a 0.9 wt% sodium chloride solution or a 5 wt% glucose aqueous solution.
33. The injection as claimed in claim 32, wherein the concentration of uricase in the injection containing 0.9wt% sodium chloride solution is 0.2-4mg / mL, and the concentration of uricase in the injection containing 5wt% glucose aqueous solution is 1-4mg / mL.
34. The injection as claimed in claim 32, wherein the pH of the injection is 7.5 to 8.
1.
35. Use of the uricase according to any one of claims 1 to 3, or the modified uricase according to claim 4 or 5, or the pharmaceutical composition according to any one of claims 6 to 31 in the preparation of a medicament for reducing uric acid levels in mammalian body fluids and tissues or treating hyperuricemia.
